Research, Drug Development & Manufacturing

2A Biosciences is a drug discovery company developing Serotonergic Anti-Inflammatories (SAIs) — non-hallucinogenic 5-HT2A receptor agonists that harness the peripheral anti-inflammatory properties of psychedelics without behavioural effects. Co-founded by pharmacologists Charles D. Nichols and David E. Nichols, the company's near-term programs target dermatological inflammatory conditions, with a broader platform addressing autoimmune and cardiovascular disease. The company has completed an oversubscribed seed round backed by biotech and psychedelic VCs.

International and interdisciplinary research group investigating consciousness, including altered-state and psychedelic-relevant domains.

ARQ National Psychotrauma Centre is a leading Dutch institute specializing in the treatment and research of complex psychotrauma and PTSD, with roots in addressing the psychological wounds of World War II since 1945 and now one of Europe's foremost psychotrauma centers. ARQ is one of nine European sites conducting MAPS-affiliated clinical trials of MDMA-assisted therapy for PTSD, and integrates medication-assisted approaches including MDMA and ketamine into its high-intensity trauma treatment programs in partnership with Leiden University Medical Center.

AZ Delta is a major Belgian hospital group headquartered in Roeselare, Flanders, operating four campuses with 1,403 approved beds. It participates in the multi-centre BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine's safety as an adjunct sedative in severe traumatic brain injury.

AZ Sint-Jan Brugge-Oostende AV is a leading Belgian teaching hospital in Bruges with a dedicated Clinical Trial Center (CTC) that sponsors and participates in academic and commercial drug studies. Its Department of Anesthesiology and Intensive Care Medicine is a confirmed site in the BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine's role in severe traumatic brain injury management.

AZ Turnhout is a general hospital in Turnhout, Antwerp province, Belgium, providing comprehensive medical and surgical care to the northern Campine region. Its Department of Anesthesiology and Intensive Care Medicine is a confirmed site in the BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine as an adjunct sedative in severe traumatic brain injury patients.

Researchers at Aarhus University are undertaking studies investigating how and why people in Denmark microdose. The aim of this research is to generate knowledge on potentially new forms of self-care emerging outside the national healthcare system in Denmark. Led by Margit Anne Petersen at the Centre for Drug and Alcohol Research, the project explores areas where the healthcare system potentially fails to accommodate patients.

AbbVie (NYSE: ABBV) is a global biopharmaceutical company and one of the first large pharma entrants in next-generation psychedelic medicine. In May 2024, AbbVie partnered with Gilgamesh Pharmaceuticals ($65M upfront, up to $1.95B in milestones) to develop novel CNS therapies including neuroplastogens. In August 2025, AbbVie acquired bretisilocin (GM-2505) — a short-acting IV serotonergic psychedelic (DMT analog) from Gilgamesh — for up to $1.2B, marking one of the largest psychedelic drug deals in history. Bretisilocin's Phase 2a data showed a -21.6 point MADRS reduction at Day 14 (p=0.003). AbbVie continues to collaborate with Gilgamesh Pharma Inc. (Gilgamesh's spin-off) on earlier-stage programmes.

Academic Medical Center, commonly abbreviated AMC, is the Amsterdam academic hospital now operating as part of Amsterdam UMC. It combines tertiary care, medical education, and clinical research linked to the University of Amsterdam.

Amsterdam UMC (AMC-UvA) is one of the leading academic medical centers in the Netherlands, uniting the medical faculties of the University of Amsterdam and Vrije Universiteit Amsterdam with extensive clinical and translational research programs. The center has participated in psychedelic research including psilocybin microdosing studies, contributing to the Netherlands' growing academic investigation of psychedelic-assisted therapy.

Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital) is a psychiatric and neurological teaching hospital in Guangzhou, China, affiliated with Guangzhou Medical University and active in clinical research.

Very small Canadian biotech developing KRN-101, a natural psilocybin formulation for cancer-related psychological distress. Market capitalisation fell below C$300,000 in 2024, with minimal operating activity and limited financing capacity.

Alef Trust is a UK-based transpersonal psychology educational institute founded by Emeritus Professor Brian Les Lancaster, offering an MSc in Consciousness, Spirituality & Transpersonal Psychology validated by Liverpool John Moores University and a professional certificate in Psychedelics, Altered States & Transpersonal Psychology taught by Dr. David Luke (Imperial College) and other leading researchers. The institute also offers collaborative PhDs and open learning courses integrating consciousness studies, parapsychology, and integrative healing traditions.

The Alexander Shulgin Research Institute (ASRI) was founded in 2021 by Dr. Nicholas Cozzi, Dr. Paul Daley, and the late Ann Shulgin, continuing the legacy of chemist Alexander Shulgin. The institute maintains the Shulgin Vault — a repository of over 500 compounds synthesized by Shulgin and ASRI scientists. Lead candidate ASR-3001 (5-MeO-iPALT) is an orally active, fast-acting tryptamine with a mild internal psychedelic profile and no visual hallucinations, near IND-ready for psychiatric disorders. ASR-2001 is a non-hallucinogenic compound producing mental clarity.

Algernon Pharmaceuticals (also known as Algernon Health / Algernon NeuroScience) is the first company in the world to test DMT as an emergent treatment for ischemic stroke and traumatic brain injury. Their lead candidate AP-188 uses sub-hallucinogenic IV DMT to promote neuroplasticity and neuroprotection. Phase 1 completed at the Centre for Human Drug Research in Leiden; Phase 2a stroke trial planned.

Full-service early-phase CRO with dedicated psychedelic clinical trial teams, specialized set-and-setting units, and integrated capabilities from preclinical support through early clinical proof-of-concept.

Alvarius Pharmaceuticals is an Irish bio-pharmaceutical company developing 5-MeO-DMT-based therapies for addiction and substance use disorders. Founded in 2021 and based in Dublin, the company conducts preclinical studies in collaboration with University College Dublin, combining acute 5-MeO-DMT administration with guided psychotherapy. Alvarius raised €5.5M in 2023 and has filed one patent.

US network of poison centers and national data system (NPDS) for toxicology and pharmacovigilance surveillance.

Apex Labs Ltd. is a private Canadian clinical-stage company developing psilocybin treatments for depression, anxiety, and PTSD, with a focus on the Veteran community. The company is advancing two parallel Phase 2b programmes: APEX-52 (take-home oral microdose psilocybin, the first of its kind in a Phase 2b trial) and APEX-90 (in-clinic macrodose psilocybin with assisted psychotherapy). Trials are running across Canada, the US (Yale School of Medicine PK study), and Israel (Tel Aviv University Sagol Brain Institute + Be'er Yaakov Mental Hospital, approved June 2025).

Arcadia Medicine is a San Francisco-based biotech developing safe entactogens for mental health disorders. Their lead candidate AM-1002 is a patented non-racemic MDMA formulation that received FDA IND clearance in October 2025 for Phase 1 trials in generalized anxiety disorder. Backed by investors including Sam Altman and Coinbase co-founder Fred Ehrsam.

Assistance Publique – Hôpitaux de Paris (AP-HP) is France's largest public hospital system, comprising 39 hospitals including Pitié-Salpêtrière and Sainte-Anne, and serving as Europe's leading academic medical center complex with extensive clinical research infrastructure. AP-HP institutions actively contribute to psychedelic medicine research, including participation in COMPASS Pathways' Phase 3 psilocybin trials for treatment-resistant depression and ketamine studies through the Paris Brain Institute.

Assistance Publique Hôpitaux de Marseille (AP-HM) is the public hospital authority of Marseille, France, comprising four major hospital groups and operating as one of the largest university hospital centers in Europe with extensive clinical research infrastructure. AP-HM has been involved in psychedelic medicine research through its clinical trial network, contributing to France's emerging landscape of psychiatry trials exploring psychedelic-assisted therapies.

Assiut University is a major public university in Upper Egypt whose Faculty of Medicine Department of Neurology and Psychiatry has contributed to ketamine research in treatment-resistant depression. The department conducted a double-blind randomized controlled trial of ketamine for TRD with psychiatric comorbidities, published in the Journal of Affective Disorders, establishing Assiut as a participant in the broader clinical research landscape relevant to psychedelic medicine.

AstraZeneca is a British-Swedish multinational biopharmaceutical company developing medicines across oncology, cardiovascular, respiratory, and neurological areas, with psychiatric products that intersect with psychedelic research contexts. AstraZeneca's antidepressants and psychiatric medications have featured as active comparators in landmark psychedelic clinical trials, including the influential psilocybin vs. escitalopram depression study at Imperial College London.

Clinical-stage psychedelic company that also functions as a strategic-corporate capital allocator through legacy atai platform investments and deal activity in the sector.

Attikon University General Hospital is one of Greece's largest university hospitals, affiliated with the National and Kapodistrian University of Athens Medical School and serving as a major center for specialist clinical care and research in the greater Athens region. The hospital has participated in clinical trials relevant to psychedelic medicine research, contributing to Greece's engagement with emerging psychiatric treatments including ketamine and esketamine for treatment-resistant depression.

WHO primary clinical trial registry for Australia and New Zealand, used for trial discovery and protocol metadata. Psychedelic relevance: registry infrastructure includes psychedelic trial records via search, but no dedicated psychedelic evidence vertical.

UK-based biopharmaceutical company developing ketamine and esketamine-based treatments for alcohol use disorder and addiction. AWKN-001 (IV ketamine combined with cognitive behavioural therapy) is in Phase 3 clinical trials in the UK for alcohol use disorder. AWKN-002, an esketamine oral thin film formulation, is in pre-IND development for the US market.

The B.R.A.I.N. Lab at UBC is actively investigating the potential of psychedelic-assisted therapy for treating opioid and other substance use disorders. Affiliated with the BC Centre on Substance Use (BCCSU), the lab conducts clinical trials exploring how psilocybin and psychotherapy can support behavioral change in addiction medicine.

The BC Centre on Substance Use (BCCSU) is an academic centre based in British Columbia that conducts research, develops clinical guidance and training, and supports evidence-based treatment and policy for substance use. It partners with health authorities, academic institutions, and community providers to improve care and reduce harms.

Bar-Ilan University conducts diverse psychedelic research, ranging from the molecular mechanisms of drug action to the study of 'adaptive dissociation' in trauma survivors. Their work also includes innovative AI simulations of psychedelic experiences and narratives.

Bar-Ilan University is a public research university in Ramat Gan, Israel, founded in 1955; it combines broad secular academic programs with Jewish studies and hosts multiple research centers across the sciences and humanities.

Academic medical center in Houston affiliated with multiple Texas Medical Center hospitals. Conducts psilocybin and MDMA clinical trials for veteran PTSD in partnership with the Michael E. DeBakey VA, and houses the ELIPSIS program — a dedicated initiative on the ethical and legal implications of psychedelics in society.

Bayside Health, operating as Alfred Health, is a Melbourne-based public healthcare network comprising The Alfred, Caulfield Hospital, and Sandringham Hospital, and serves as the principal teaching hospital partner for Monash University's Clinical Psychedelic Lab. As host institution for Victoria's major trauma and psychiatric services, it provides clinical infrastructure supporting Australia's psychedelic therapy programmes following the 2023 TGA rescheduling.

Fundación Beckley Med is a Barcelona-based psychedelic research and education organisation, partnered with the UK's Beckley Foundation, that funds and disseminates psychedelic-assisted therapy studies and provides professional training through institutional affiliations with MAPS, Grof Legacy, and CIIS. It collaborated with CITA Clinic to deliver experimental ketamine treatment to patients with treatment-resistant depression in Spain.

Israeli psychiatric hospital near Tel Aviv that served as a key clinical trial site for MAPS-sponsored MDMA-assisted psychotherapy for PTSD, with Dr. Moshe Kotler serving as principal investigator. Beer Yaakov is slated to participate in future MAPS Israel trials treating post-October 7 PTSD among Nova festival survivors and soldiers, in collaboration with the Israeli Ministry of Health.

Beijing Chaoyang District Third Hospital is a Second Class B psychiatric specialist public hospital and the Chaoyang District Mental Health Center, providing mental health services to approximately 3.8 million district residents through seven inpatient wards and 35 departments. It has participated in multi-centre psychiatric clinical trials in China, including studies on cognitive-behavioural therapy for schizophrenia and depression outcomes research.

Beijing Daxing District Xinkang Hospital (北京市大兴区心康医院), also designated as the Daxing District Mental Health Institute, is a Class II Public Welfare psychiatric institution under Beijing's Daxing District Health Commission. Its Department of Psychiatry and Mental Health has contributed to Chinese psychiatric research, including studies on perinatal depression and other mental health outcomes.

Beijing Sanbo Brain Hospital (首都医科大学三博脑科医院) is a leading private specialised neurological hospital founded in 2004, affiliated with Capital Medical University as its Eleventh Clinical School, with 256 beds dedicated to neurosurgery, epilepsy, cerebrovascular disease, and functional neuroscience. Its anesthesiology department participates in multi-centre trials investigating ketamine and related anesthetic agents in neurosurgical settings.

China's premier neurology and neurosurgery hospital, affiliated with Capital Medical University and home to the National Clinical Research Center for Neurological Diseases. Conducted the PASSION trial — a randomized, placebo-controlled study of intraoperative ketamine for depression in neurosurgical patients.

Benha University is a public Egyptian university whose Faculty of Medicine and Psychiatry Department has contributed to research on ketamine and esketamine for treatment-resistant depression within the Egyptian academic and clinical context. As a key medical institution in the Nile Delta region, it participates in collaborative psychiatric research networks exploring novel pharmacological treatments for mood disorders.

Benuvia is a US-based contract development and manufacturing organization (CDMO) and API supplier specialising in psychedelic and controlled-substance therapeutics. Operating an 83,000 sq ft GMP facility in Round Rock, Texas, the company holds DEA authorisation to manufacture psilocybin, psilocin, DMT, MDMA, and 5-MeO-DMT. In March 2025, Benuvia was awarded a five-year NIH/NIDA contract for GMP psilocybin synthesis and received ANVISA GMP certification from Brazil. The company also holds the FDA-approved cannabinoid drug SYNDROS®.

UC Berkeley Center for the Science of Psychedelics (BCSP), founded in September 2020 by a multidisciplinary faculty group including neuroscientist Michael Silver and author Michael Pollan, conducting psilocybin research into cognition, perception, emotion, and their neural bases in the human brain. BCSP's four pillars of basic science, journalism, culture, and community have established it as a leading interdisciplinary hub for psychedelic research and public engagement, producing The Microdose newsletter and a global clinical trials map.

Berry Consultants is a US statistical consulting firm specializing in Bayesian adaptive clinical trial design, with expertise in platform trials and adaptive dose-finding studies increasingly applied in psychedelic and psychiatric drug development. The firm has engaged with regulatory frameworks for psychedelic medicines, including commenting on FDA guidance for clinical trials involving psilocybin and MDMA.

BetterLife Pharma (CSE: BETR / OTC: BETRF) is a Canadian biotech developing BETR-001, a first-in-class non-hallucinogenic LSD derivative (2-bromo-LSD / BOL-148) for MDD, anxiety, and neuropathic pain. BETR-001 was acquired from Transcend Biodynamics LLC and activates the 5-HT2A receptor at 60% efficacy — sufficient for neuroplastogenic antidepressant effects but below the threshold for hallucinogenic effects. A composition of matter patent was granted January 2025, IND filing projected H1 2026.

Bexson Biomedical is a US private biotech developing BB106, a subcutaneous wearable formulation of ketamine delivered via its proprietary SEVALENT™ platform device. The formulation is designed to provide precise, extended ketamine dosing for chronic pain and depression outside of clinic settings. As of 2023 the company was conducting IND-enabling studies.

Biomia is a Copenhagen-based synthetic biology company developing novel plant-inspired drug candidates for unmet medical needs in pain, addiction, and depression. Using a proprietary AI-assisted drug discovery engine and fermentation-based biomanufacturing platform, the company engineers Monoterpene Indole Alkaloid (MIA) derivatives — a large family of plant-derived bioactive compounds including ibogaine analogs — with optimised halogenation to improve ADME properties and therapeutic profiles.

Biomind Labs (NEO: BMND) is a Canadian clinical-stage biopharmaceutical company developing inhaled DMT, sublingual 5-MeO-DMT, and mescaline-class compounds across TRD, Alzheimer's-related depression, obesity/neuroinflammation, and Parkinson's disease. Founded in 2019 and publicly listed via RTO in July 2021, the company's clinical work is primarily conducted in Brazil (UFRN, PI Prof. Dráulio de Araujo) and Argentina (Dr. Martin Bruno). Their BMND08 (sublingual 5-MeO-DMT for Alzheimer's depression) achieved a 100% remission rate in a Phase 2 RCT at subpsychedelic doses (February 2024) and is now advancing to FDA-directed Phase 3 via a proprietary nano-formulation platform with FDA Breakthrough Therapy Designation planned. BMND01 (inhaled DMT) is in Phase 2 for TRD with the unique advantage of a ~10-minute experience duration vs hours for psilocybin or LSD. Note: master list originally classified as private, but is publicly listed on NEO/CBOE.

Bispebjerg Hospital is a major Copenhagen university hospital and the coordinating site for PsyPal, the EU-funded multi-centre trial investigating psilocybin-assisted therapy for anxiety and existential distress in patients with ALS—the first European publicly-funded psychedelic trial of its kind. Affiliated with the University of Copenhagen, the hospital leads Nordic clinical research into psychedelic-assisted therapies for neurological and palliative conditions.

Braxia Scientific Corp. (CSE: BRAX) is a Canadian publicly-listed medical research company that operates a network of ketamine and psilocybin treatment clinics across Ontario and Quebec through its subsidiary Canadian Rapid Treatment Centre of Excellence, and conducted Canada's first multi-dose Phase II psilocybin randomized controlled trial for treatment-resistant depression. The company received Health Canada Special Access Program approval to deliver psilocybin-assisted therapy in Ontario and holds government-funded grants for ketamine trials in bipolar depression, led by researchers Dr. Roger McIntyre and Dr. Joshua Rosenblat.

Brazil's public clinical trial registry platform for experimental and non-experimental studies in humans. Psychedelic-specific indexing is not offered as a dedicated registry surface.

Major academic medical center in Boston affiliated with Harvard Medical School and part of the Mass General Brigham health system. Researchers at BWH are active in the emerging field of psychedelic-assisted therapy, including psilocybin studies for gastrointestinal conditions and ethical frameworks for psychedelic pain research.

Bright Minds Biosciences (NASDAQ: DRUG) is a Vancouver-based biotech developing highly selective serotonergic agonists for neurological and psychiatric disorders. Lead asset BMB-101, a 5-HT2C agonist, is in Phase 2 for drug-resistant epilepsy (BREAKTHROUGH study, positive Phase 2 results January 2026). BMB-201 is a 5-HT2A/2C agonist showing preclinical efficacy in pain and migraine models (outperformed sumatriptan, Sept 2025). BMB-202 is a selective 5-HT2A agonist with antidepressant profile in development for MDD.

The James J. Peters VA Medical Center (Bronx VA) in New York is home to the Center for Psychedelic Psychotherapy and Trauma Research—a joint initiative with Mount Sinai's Icahn School of Medicine led by Dr. Rachel Yehuda—which pioneered the first FDA-approved randomized MDMA-assisted psychotherapy trial within the VA system and has conducted ketamine-based trials for chronic PTSD and suicidal ideation in veterans. The center is one of nine VA facilities participating in the expanded national VA psychedelic-assisted therapy research program.

The Bronx Veterans Medical Research Foundation (BVMRF) is a 501(c)(3) nonprofit that administers extramural research funding for the James J. Peters VA Medical Center and VA Hudson Valley Health Care System, supporting mental health, biomedical, and rehabilitation research focused on veteran populations. In the psychedelic context, it provides the administrative research infrastructure supporting MDMA-assisted therapy for PTSD and ketamine studies conducted at the Bronx VA's Center for Psychedelic Psychotherapy and Trauma Research.

Brooke Army Medical Center (BAMC) at Joint Base San Antonio is the US Army's flagship medical institution and the Department of Defense's only Level I Trauma Center, and has been a primary site in multi-center randomized controlled trials investigating ketamine for antidepressant-resistant PTSD in active duty military and veterans. BAMC researchers have also contributed to pilot studies on service members' perspectives on psychedelic-assisted therapies including MDMA and psilocybin for PTSD and traumatic brain injury.

Bruyère Health Research Institute is the academic research arm of Bruyère Health in Ottawa, Canada, fully affiliated with the University of Ottawa and specializing in palliative care, aging, and rehabilitation research—areas with growing overlap with psychedelic-assisted therapy applications. The institute contributed to a major Ontario population study examining schizophrenia risk following hallucinogen-related emergency department visits, generating safety evidence informing screening protocols for psychedelic clinical trials.

CB Therapeutics is a Carlsbad, California-based synthetic biology company developing biosynthetic psychedelic compounds and their novel analogues using a proprietary yeast fermentation platform. Founded in 2015, the company has raised $11.62M from investors including Y Combinator, Pioneer Fund, and re.Mind Capital. CB Therapeutics has achieved biosynthesis of psilocybin, psilocin, DMT, and MDMA analogs, holds seven granted patents with twelve pending, and has partnered with atai Life Sciences and Cleveland Clinic for clinical supply. Its PsyVault™ platform houses the largest collection of biosynthetic psychedelics and analogues.

CH TAC LLC (Cluster Headache-Trigeminal Autonomic Cephalalgia, LLC) is a US non-profit research entity that co-sponsored Yale University's Phase 1 psilocybin trials for episodic and chronic cluster headache, in partnership with Heffter Research Institute and Ceruvia Lifesciences.

A residential off-campus of CHRIST (Deemed to be University), Bangalore located in Lavasa near Pune, India; the Pune Lavasa Campus offers undergraduate and postgraduate programs and is promoted as a hub for analytics and allied disciplines.

CHU de Québec–Université Laval is Quebec City's largest university hospital network, affiliated with Université Laval and serving as a major clinical research hub. It hosts the P3A Study Group led by Dr. Michel Dorval (Oncology Division), conducting a psilocybin-assisted psychotherapy trial for existential distress in patients with advanced cancer.

The California Institute of Integral Studies (CIIS) launched the world's first university-affiliated Psychedelic-Assisted Therapies and Research Certificate Program in 2015, establishing the gold standard for post-graduate psychedelic clinician training, with cohorts now also offered a B.S. in Psychedelic Studies and a KAP clinic. Based in San Francisco, CIIS is a non-profit graduate university pioneering integral approaches to consciousness, therapy, and psychedelic medicine.

COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.

Swedish full-service CRO with early-phase concentration, integrated site network, and in-house capabilities spanning project management, monitoring, biometrics, pharmacovigilance, and medical writing.

EU clinical trial public portal with explicit psilocybin trial records currently visible.

Columbia University Irving Medical Center (CUIMC) is a major academic medical centre in New York City, integrating Columbia University's Vagelos College of Physicians and Surgeons with NewYork-Presbyterian Hospital and conducting research across neuroscience, psychiatry, and translational medicine. CUIMC serves as the primary clinical site for the Ketamine Biomarker Validation trial (NCT07307768), an EEG-based Phase I study examining dose-response relationships across three ketamine infusion levels in adults with treatment-resistant major depressive disorder.

CaaMTech is a US psychedelic drug discovery company based in Issaquah, Washington, focused on novel tryptamine chemistry. Founded around 2018, the company raised $22M in a 2021 Series A and holds a CRADA with NIH/NIDA and a research collaboration with UMass Dartmouth. Its two flagship compound series are Prophoria™ (4-AcO-DMT analogues) and Amphoria™ (4-HO-MiPT analogues), which the company is developing as improved psychedelic therapeutics with potentially more targeted and safer profiles than existing compounds.

The California Pacific Medical Center Research Institute (CPMCRI) is the academic research arm of California Pacific Medical Center in San Francisco, whose physician-scientists have contributed to the Bay Area’s psychedelic research ecosystem through advisory roles at the CIIS Center for Psychedelic Therapies and Research and collaborative ties to MAPS for evaluating MDMA-assisted therapy. CPMCRI conducts translational and clinical research across oncology, neurology, and psychiatry in partnership with UCSF and other Bay Area institutions.

Cambridge Cognition (AIM: COG) is a UK-based cognitive technology company that develops and licenses the CANTAB neuropsychological assessment platform, validated in over 3,000 publications and widely adopted in psychedelic clinical trials—including psilocybin and MDMA studies—to objectively measure cognitive outcomes at baseline, during, and after treatment. CANTAB’s digital cognitive assessments have become a de facto standard endpoint tool in psychiatric drug development, supporting the field’s progression through Phase 2 and Phase 3 psychedelic trials.

The Cambridge Psychedelic Research Group (CPRG) is a collaborative initiative aimed at accelerating the development of innovative psychedelic therapies. Led by Dr. Liliana Galindo, the group conducts multidisciplinary research and clinical trials for severe mental health conditions, including PTSD and treatment-resistant depression.

Canisius-Wilhelmina Hospital (CWZ) is a major teaching hospital in Nijmegen, Netherlands, whose Department of Neurology has contributed to psychedelic research including an evidence-based review of LSD and psilocybin for chronic pain management, examining serotonin-2A receptor-mediated neuroplastic mechanisms. Situated in the Netherlands—one of Europe’s most active countries for psychedelic research—CWZ participates in neurological research exploring psychedelic compounds as therapeutic agents for pain and psychiatric conditions.

Cardiff University Brain Research Imaging Centre (CUBRIC) is a brain imaging centre at Cardiff University in Cardiff, Wales. It hosts advanced MRI, MEG, EEG and brain-stimulation facilities for research into brain structure and function.

Global CDMO supporting pharmaceutical development and manufacturing, including explicit psychedelic-related cGMP drug-product programs in sponsor disclosures.

Established supplier and CDMO platform (with Cayman Pharma) providing cGMP API manufacturing, including psychedelic compounds for clinical-trial pathways and analytical support.

U.S. clinical site network and clinical sciences platform focused on CNS and early-phase development, with dedicated psychedelic research expertise and integrated patient recruitment operations.

The Center for Medicinal Cannabis Research (CMCR) is a California state-funded research program at UC San Diego that rigorously evaluates the medical efficacy and safety of cannabis and cannabinoids through placebo-controlled clinical trials, with regulatory expertise in Schedule I research that overlaps with psychedelic medicine. CMCR has been cited in psychedelic trial contexts for its methodological framework and experience navigating DEA/FDA processes for controlled-substance clinical research applicable to psilocybin and MDMA studies.

The Center for the Neuroscience of Psychedelics at MGH (Mass General Brigham) focuses on understanding how psychedelics impact brain structure and function to optimize treatments for mental illnesses. Led by Dr. Jerrold Rosenbaum, their initial research concentrates on psilocybin for treatment-resistant depression.

The Central Institute of Mental Health (ZI Mannheim) is a leading German psychiatric research institute affiliated with Heidelberg University, and under Prof. Dr. Gerhard Gründer is one of Europe’s foremost centers for psychedelic research—co-leading EPIsoDE, Germany’s first federal government-funded (BMBF, €2.2M) Phase II RCT of psilocybin for treatment-resistant depression, and receiving one of the first compassionate-use approvals for psilocybin in Germany and the EU, with results published in Lancet Psychiatry in 2025. The institute also conducts molecular neuroimaging research on MDMA and psilocybin mechanisms, and has reported successful ketamine treatment outcomes in treatment-resistant depression.

The Central Institute of Mental Health (Zentralinstitut für Seelische Gesundheit, ZI) is a psychiatric research and treatment center in Mannheim affiliated with the Medical Faculty Mannheim of Heidelberg University, providing research, teaching and clinical services in psychiatry, psychotherapy, child and adolescent psychiatry, psychosomatic medicine and addiction medicine.

Central Michigan University (CMU) is a public research university located in Mount Pleasant, Michigan. It offers undergraduate, graduate, and professional programs on its main campus, regional sites, and through online delivery.

GHU Paris Psychiatrie et Neurosciences (the current form of historic Hôpital Sainte-Anne) is France's leading university psychiatric hospital, pioneering psychedelic research under Jean Delay from the 1930s and now leading a 2024 ANR-funded psilocybin RCT aimed at dissociating therapeutic effects from acute psychedelic experience in treatment-resistant depression.

University hospital in Charleroi, Belgium affiliated with the Université Libre de Bruxelles. Participates in clinical trials for psychiatric and neurological conditions, including studies in the emerging area of esketamine and rapid-acting antidepressant therapies.

The Centre for Human Drug Research (CHDR) in Leiden, Netherlands is a world-class early-phase clinical research organization conducting approximately 60 trials per year, with a specialist psychiatry department that has become one of Europe’s leading sites for psychedelic compound research—including psilocybin, DMT, MDMA, and ketamine—using advanced tools such as the NeuroCart CNS battery and EEG to quantify pharmacodynamic endpoints. CHDR has conducted first-in-human studies with novel non-hallucinogenic neuroplastogens and intravenous DMT regimens, establishing it as a key early-phase partner for psychedelic drug development.

The Centre for Neurology Studies (CNS) is a private clinical research centre in Surrey, British Columbia, and one of Canada’s few dedicated neuroscience-focused clinical trial organizations, conducting Health Canada and FDA-approved studies in mental health, neurodegenerative disorders, and brain health. Operating within British Columbia’s growing clinical trials ecosystem, CNS has participated in research on novel psychiatric treatments relevant to the emerging psychedelic medicine field.

The Centre hospitalier de l’Université de Montréal (CHUM) is one of Canada’s leading academic health centres and home to psychiatrist Dr. Nicolas Garel, co-developer of the ‘Montreal Model’—a ketamine-assisted psychotherapy protocol for severe treatment-resistant depression that integrates psychedelic-inspired non-pharmacological adjuncts with structured psychiatric care. The MUSIK trial, conducted at CHUM and published in the British Journal of Psychiatry, demonstrated sustained 8-week depression relief and established that ketamine’s mystical experiences are central to its antidepressant mechanism.

Reference standards manufacturer supporting analytical, forensic, and clinical-lab workflows, with psychedelic standards in its certified catalog.

Ceruvia Lifesciences is a US-based clinical-stage biopharmaceutical company founded in 2017 by philanthropist Carey Turnbull, focused on developing neurotransformational medicines for neurological and psychiatric disorders. The company was the world's first producer of cGMP-certified LSD and its non-hallucinogenic analogue BOL-148. Ceruvia is advancing SYNP-101 (synthetic psilocybin) through Phase 2 trials for OCD, alcohol use disorder, and migraine/headache disorders, and NYPRG-101 (BOL-148) for cluster headache. Collaborators include Yale University, the Heffter Research Institute, Usona Institute, NYU, and Clusterbusters.

Cessatech A/S is a Copenhagen-based paediatric biotech developing CT001, a first-in-class intranasal ketamine/sufentanil combination analgesic for acute pain in children aged 1–17, with an EMA Marketing Authorisation Application submitted in 2025 and approval expected in 2026.

The Chair of Entrepreneurial Culture (Cátedra de Cultura Empresarial) at the University of Valencia, administered via the ADEIT Fundación Universidad‑Empresa, promotes entrepreneurial initiative among students and connects them with business leaders through programs such as ‘Qui pot ser empresari?’.

The MIND Foundation partnered with Charité – Universitätsmedizin Berlin, one of Europe's largest university hospitals. Charité is affiliated with Humboldt University and Free University Berlin. This partnership sees researchers at the hospital carrying out clinical studies with psilocybin in patients with treatment-resistant depression. Studies also take place concurrently at the Central Institute for Mental Health Mannheim.

The Center for Forensic Mental Health (CFMH) at Chiba University is a university research and education center focused on forensic psychiatry and social mental health. It provides training for medical and legal professionals and conducts research on diagnosis, treatment, and social systems concerning offenders with mental disorders and juvenile delinquency.

The Children’s Hospital of Eastern Ontario (CHEO) is a leading Canadian pediatric tertiary care hospital in Ottawa affiliated with the University of Ottawa; CHEO Research Institute supports over 250 researchers, and CHEO is conducting a clinical trial of IV ketamine for suicidal ideation in youth.

The Children’s Hospital of Fudan University (CHFU) is China’s top-ranked pediatric hospital, affiliated with Fudan University Shanghai Medical College, and is a trial site for esketamine-based therapies in rare pediatric neurological conditions including a clinical study of esketamine for Rett syndrome.

Children's National Research Institute is the research enterprise of Children's National Hospital in Washington, D.C., conducting translational and clinical research across pediatric disciplines. It is a site in the KESETT trial (Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial), investigating ketamine as an adjunctive therapy for refractory pediatric status epilepticus.

China Medical University (中国医科大学), based in Shenyang, Liaoning, is a leading Chinese medical institution conducting research on ketamine and esketamine for treatment-resistant depression and other psychiatric conditions. Its affiliated hospitals and departments participate in multi-centre esketamine trials and publish meta-analyses on ketamine's antidepressant mechanisms.

WHO primary trial registry for China with broad trial metadata coverage. Psychedelic-specific datasets are not presented as a dedicated public vertical.

Citeline (formerly Informa Pharma Intelligence) is a global pharmaceutical data and clinical intelligence platform providing AI-driven drug pipeline tracking, trial monitoring, and R&D analytics to life sciences organisations. It is referenced as a data source in the Department of Defense PTSD Adaptive Platform Trial involving SLS-002 (esketamine intranasal spray).

Clairvoyant Therapeutics is a Canadian clinical-stage biotech developing synthetic psilocybin for alcohol use disorder (AUD). The company ran a fully randomized, double-blinded Phase IIb multi-country trial in the EU and Canada enrolling 154 participants, with topline data anticipated in early 2025. Founded in 2021 in Vancouver, a proposed acquisition by Psyence Biomed (Nasdaq: PBM) for $500K in September 2024 fell through following due diligence.

Commercial intelligence platform with clinical, regulatory, and real-world evidence datasets for biopharma decision support.

Clearmind Medicine is an Israeli-American biotech developing CMND-100, a proprietary oral MEAI (5-methoxy-2-aminoindane) formulation for alcohol use disorder. First patient dosed in June 2025 in their multinational Phase 1/2a trial across Yale, Johns Hopkins, and Hadassah Medical Center. Positive first cohort top-line results reported November 2025.

UK-based specialist CNS and psychiatry-focused clinical research organization combining select CRO services, dedicated trial sites, participant recruitment, and psychedelic therapist training for complex mental-health studies.

Clexio Biosciences is a private Israeli clinical-stage CNS company founded in 2018 by Teva Pharmaceuticals R&D veterans. Their lead programme CLE-100 is a once-daily oral tablet formulation of esketamine for MDD — distinguished from the FDA-approved Spravato (intranasal, in-clinic) by enabling outpatient, at-home use. Phase 2 CLEO study results showed a promising safety profile and encouraging efficacy specifically in post-COVID MDD subgroups; the Phase 2 SOLEO study (NCT06340958, higher dose, stricter treatment-resistance criteria) enrolled first patients April 2024 and reached 50% enrollment by December 2024. CLE-100 holds multiple US method-of-use patents (2024). In December 2025, Clexio spun out its muscarinic agonist programme (CLE-905) into a new entity, Syremis Therapeutics, which raised $165M Series A co-led by Dexcel Pharma and Third Rock Ventures. Co-founders Kogan, Levy, and Kagan simultaneously lead Syremis; Clexio continues independently with CLE-100 and preclinical CLE-043.

US National Library of Medicine registry and results database with broad global trial coverage, including many psychedelic studies.

Global CNS-focused full-service CRO operating Phase 1 research units and end-to-end trial services, with documented psychedelic and hallucinogenic clinical studies and controlled-substance trial infrastructure.

Collaborations Pharmaceuticals is a Raleigh, North Carolina-based drug discovery company using generative AI to design novel psychoplastogens for substance use disorders. Its lead candidate DM506 is a non-hallucinogenic, non-cardiotoxic synthetic ibogamine derivative (ibogaminalog) that has shown preclinical efficacy in reducing cue-induced heroin-seeking and modulating prefrontal cortex GABA currents in opioid use disorder models.

Research with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.

The Copenhagen Trial Unit (CTU), Centre for Clinical Intervention Research, is a non-specialty clinical research unit at Rigshospitalet (Copenhagen University Hospital), supporting rigorous randomised clinical trials and systematic reviews across all medical disciplines since 2000. Located at the same hospital campus as the Neurobiology Research Unit conducting active psilocybin neuroimaging studies, CTU provides the trial methodology, statistical expertise, and conduct infrastructure that enables clinical psychedelic research in Denmark.

Canadian biotech developing biosynthetic psilocybin through its Vocan Biotechnologies subsidiary. Vocan's proprietary fermentation-based process produces pharmaceutical-grade psilocybin without mushroom cultivation. Signed a partnership with Cube Psytech for psychedelic drug development in December 2023.

Cornell University is a private Ivy League research university founded in 1865 with its main campus in Ithaca, New York, United States. It has a land-grant mission and operates additional campuses and programs in New York City and abroad.

Australian psychedelic medicines supply and commercialization venture focused on GMP-grade MDMA and psilocybin pathways for clinical and authorized-prescriber use.

Cy Biopharma AG is a Swiss biotech company developing novel psilocybin-derived small molecule therapies for chronic pain and other CNS conditions, with a focus on rare and orphan indications. Operating from Baar, Switzerland, Cy screens biochemical extracts combined with serotonin receptor agonists to create new molecular entities, and has formed a strategic supply and collaboration partnership with Australian life sciences company Bioxyne Limited for Australasia and global markets.

CZECRIN (Czech Clinical Research Infrastructure Network) is the Czech national node of the pan-European ECRIN-ERIC research infrastructure, supporting non-commercial academic clinical trials across Czech hospitals and research institutions. It has actively showcased the PSIKET001 and PSIKET002 trials — landmark double-blind comparisons of psilocybin versus ketamine for treatment-resistant depression at the National Institute of Mental Health — as flagship examples of Czech psychedelic clinical innovation.

Definium Therapeutics (formerly Mind Medicine / MindMed) is a late-stage clinical biopharmaceutical company headquartered in New York, founded in 2019 and rebranded in January 2026. Led by CEO Robert Barrow, the company applies scientific rigor to psychedelic-derived molecules to develop accessible, rapidly-acting psychiatric treatments. Its lead asset, DT120 ODT (formerly MM-120) — a pharmaceutically optimised formulation of lysergide D-tartrate (LSD) as an orally disintegrating tablet — has received FDA Breakthrough Therapy Designation for generalised anxiety disorder (GAD) and delivered compelling Phase 2b results: 65% clinical response rate and 48% remission at 12 weeks following a single dose. Three Phase 3 trials are currently underway: Voyage and Panorama (GAD) and Emerge (MDD, fully enrolled). Topline data from all three studies is expected in 2026, potentially positioning Definium for the first-ever FDA approval of an LSD-derived therapy. A second pipeline asset, DT402 (formerly MM402) — an MDMA-related compound — is in Phase 1 development for autism spectrum disorder.

Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.

DemeRx is a clinical-stage biotech developing noribogaine (DMX-1001), a non-psychedelic active metabolite of ibogaine, as a treatment for alcohol use disorder. DMX-1001 promotes neuroplasticity to repair neural circuits damaged by chronic alcohol use. Phase 1b completed with favorable safety; Phase 2 AUD trial planned for 2026, supported by a $1.7M NIH SBIR grant.

Diamond Therapeutics is a private Canadian clinical-stage company pioneering sub-perceptual (non-hallucinogenic) psilocybin therapy. Their approach focuses on low-dose psilocybin that does not produce psychedelic experiences, enabling at-home outpatient administration — a differentiated strategy from the clinic-based, high-dose psychedelic-assisted therapy model. Founded in 2018 by CEO Judith Blumstock, Diamond completed a Phase 1 single ascending dose study in healthy volunteers (n=56, 7 cohorts, December 2022) establishing a safe non-hallucinogenic dose range. Their Phase 2a GAD programme received Health Canada approval in January 2023 — the first Health Canada NOL for a psychedelic trial in GAD — and enrolled first patients at Kingston Health Sciences Centre in 2025 in the first-ever at-home microdose psilocybin study. A parallel FDA-authorized Phase 2 demoralization trial is also underway at UAB. Diamond is funded by private investors and non-dilutive public grants, including a $1.1M+ CQDM/Brain Canada drug discovery consortium launched in May 2025.

Drug Science is a UK-based independent scientific body that supports evidence-led drug policy and public education, and has played a visible role in psychedelic research translation, communication, and policy discourse.

Following an institutional review of its research priorities and stance on psychedelic-assisted therapies, Duke University has concluded the operations of the Center for Integrated Psychedelic Science (CIPS). The university remains engaged with the broader scientific community but does not currently host a dedicated center for this work.

European pharmacovigilance system for suspected adverse drug reaction reporting. Psychedelic relevance: EMA has hosted a multi-stakeholder psychedelics regulatory workshop and EudraVigilance is the key EU safety channel.

EPOPTEIA is a non-profit research institute in Greece dedicated to the scientific and cultural study of entheogens. Their work includes archaeopharmacology, the reconstruction of the ancient Eleusinian kykeon, and developing clinical infrastructure for psychedelic research in Greece.

Clinical trial technology provider (now part of Clario branding) offering neuroscience-focused eCOA and endpoint-quality services for global CNS studies, including methodologies relevant to psychedelic-assisted therapy trials.

Edith Cowan University (ECU) is a public research university based in Western Australia, Australia, with campuses in Perth and regional centres. Established as a university in 1991, it offers undergraduate and postgraduate programs across a range of disciplines and engages in research.

Ehave Inc. is a Canadian digital health company providing telemetry and data-collection platforms for precision-medicine clinical trials, including psychedelic and ketamine research; their KetaDASH product enables ketamine home-delivery monitoring for medical practitioners. The company holds an FDA-authorized IND for a ketamine EEG study in major depressive disorder.

Elkedonia is a French neuroplastogen biotech developing novel small molecules targeting the Elk-1 transcription factor, a key regulator of neuroplasticity within neuronal cells. Backed by €11 million in funding, the company is advancing clinical research into next-generation antidepressants that promote neuroplasticity without the adverse effects of traditional treatments, with CEO Delphine Charvin leading the programme.

The Center for Psychedelics and Spirituality at Emory University combines expertise in psychiatry with spiritual health to better understand the therapeutic promise of psychedelics as medicine. Launched at the end of 2022, the group works towards making psychedelic-assisted therapies more effective within a wide cultural and spiritual context.

Emotion Science (Emotion Science LLC, Denver) is an independent research and training entity associated with psychedelic and eating-disorder publications and clinician training led by Dr. Adele Lafrance.

EmpathBio Inc. is an ATAI Life Sciences subsidiary developing EMP-01, an MDMA derivative designed to preserve entactogenic therapeutic properties while reducing cardiovascular and stimulant side effects, with PTSD as the primary indication. The company completed a Phase 1 trial of EMP-01 in 32 healthy volunteers in New Zealand.

Empower Research Inc. is the corporate research entity behind Empower Psychedelics, running Health Canada-approved trials on psychedelic-assisted group therapy for first responders in partnership with MAPS Canada. The organization has also studied medically perceived benefits of psychedelics and cannabinoids among first responders and military personnel.

Empyrean Neuroscience is a New York-based biotech pioneering the use of genetic engineering of fungi and plants to develop novel neuroactive therapeutics for CNS disorders. Founded in 2019, the company launched with a $22M Series A from Spore Partners and uses CRISPR/Cas9 technology licensed from ERS Genomics to genetically modify Psilocybe cubensis, Tabernanthe iboga, and Cannabis sativa. Lead programmes include an encapsulated psilocybin mushroom drug product (IND-enabling studies) and DMT-based therapeutics for MDD, PTSD, and substance use disorders.

Australian clinical-stage biotech pioneering psychedelic-assisted therapies. In 2025, Emyria became the first company in the world to commercially deliver MDMA-assisted psychotherapy for PTSD, with insurance funding secured from Medibank. Also operates a clinical trial division and an MDMA analogue discovery program in collaboration with the University of Western Australia.

Entheos Labs is a Boston-based psychedelic medicines company founded in 2022 by Dr. Jerry Rosenbaum and Tristan Edwards, dedicated to discovering, developing, and deploying novel psychedelic medicines for unmet medical needs. The company is creating a pipeline of new chemical entities derived from overlooked natural psychedelic materials, with its lead candidate ET-01 targeting mood, anxiety, trauma, and substance use disorders.

Entropy Neurodynamics Limited (formerly Tryptamine Therapeutics Limited, renamed November 2025; ASX: ENP, OTC: TYPTF) is an Australian clinical-stage company developing psilocin-based therapies for conditions with major unmet need including fibromyalgia, binge eating disorder, and IBS. Its two-pronged strategy uses TRP-8802 (oral psilocybin) to establish clinical proof-of-concept, then advances TRP-8803 (proprietary IV psilocin formulation) for precision dosing. Phase 2a fibromyalgia and BED trials showed strong results; the world's first IV psilocin neuropsychiatric trial (TRP-8803 in BED) dosed its first patient on December 1, 2025 at Swinburne University.

Enveric Biosciences (NASDAQ: ENVB) is a clinical-stage biotech developing novel non-hallucinogenic neuroplastogenic DMT analogs for depression, anxiety, and addiction via its Psybrary™ discovery platform. Lead candidate EB-003 is a first-in-class compound designed to selectively engage both 5-HT2A and 5-HT1B receptors, delivering fast-acting antidepressant and anxiolytic effects without hallucinations. EB-003 completed pre-IND dose range studies (Aug 2025) and demonstrated positive preclinical PTSD data (July 2025), with IND filing targeted Q3 2025 and clinical initiation by end of 2025.

Equulus Therapeutics (Raleigh, NC) was founded in 2023 to develop non-hallucinogenic, non-cardiotoxic ibogaine analogs for substance use disorders. Lead candidate EQL-101 retains ibogaine’s anti-addictive efficacy while eliminating its hallucinogenic effects and cardiotoxicity (hERG inhibition). The company is advancing EQL-101 through IND-enabling studies targeting first-in-human dosing by Q4 2026. Co-founded by RTI medicinal chemist Bruce Blough and pharmacologist Kevin Murnane (LSU), who received a $2.4M NIH grant for methamphetamine use disorder research.

Erowid Center is a nonprofit educational organization and public information resource on psychoactive substances, including the Erowid Experience Vaults user-report archive and broader harm reduction materials.

Legacy EU clinical trials register still relevant for historical records and legacy IDs linked from CTIS; includes trial history relevant to psychedelic development tracking.

The European Association for Palliative Care (EAPC) is the leading European professional body for palliative care research, education, and policy, headquartered in Milan. The EAPC is a core consortium partner in PsyPal, the first EU-funded multi-site psilocybin clinical trial (€6.5M), studying psilocybin-assisted therapy for psychological distress in patients with COPD, MS, ALS, and atypical Parkinson's disease across multiple European sites.

The University of Exeter hosts a multidisciplinary psychedelic research community spanning philosophy, psychology, and neuropharmacology. Led by Professor Celia Morgan, the group explores the therapeutic potential of psychedelics for neuropsychiatric disorders and offers specialized academic programs in the field.

Biotech startup focused on biosynthetic psychedelic compounds and clinical-grade supply, with a product slate spanning psilocybin, DMT, 5-MeO-DMT, and bufotenine.

US FDA adverse-event monitoring infrastructure for regulated products. Psychedelic relevance: FDA has issued draft clinical trial guidance for psychedelic drugs and AEMS is the active public safety-monitoring surface.

US FDA adverse-event and product-problem reporting program with public safety communications and reporting channels.

The University of Applied Sciences and Arts Northwestern Switzerland (FHNW) is a public Swiss university of applied sciences offering practice‑oriented bachelor’s and master’s programs across multiple schools (engineering, business, life sciences, art & design, education, etc.) and conducting applied research, continuing education, and regional services.

The Faculty of Medical Sciences (Faculdade de Ciências Médicas, FCM) is the medical school of the State University of Campinas (Unicamp), offering undergraduate and graduate medical education, clinical services, and biomedical research through its teaching hospital in Campinas, São Paulo.

The Federal University for Latin American Integration (UNILA) is a bilingual public university at the Foz do Iguaçu tri-national border between Brazil, Argentina, and Paraguay, focused on regional integration sciences. UNILA's clinical neuropharmacology laboratory, led by Francisney Nascimento, is conducting ayahuasca trials for prolonged grief disorder and developing a randomized placebo-controlled psilocybin clinical trial.

Federal University of Rio Grande do Norte is a public research university in Brazil with active neuroscience and mental health research programmes, including work linked to psychedelic science through affiliated institutes.

The Brain Institute at the Federal University of Rio Grande do Norte is a Brazilian academic neuroscience center conducting translational research relevant to mental health and psychedelic science collaborations.

The Federal University of São Paulo (UNIFESP) is a public federal research university based in the state of São Paulo, Brazil, with multiple campuses and a strong reputation in health sciences and related programs.

Field Trip Health was a Canadian publicly traded ketamine-assisted psychotherapy company founded in 2019 that operated clinics across North America and Europe while developing FT-104, a shorter-duration psilocybin analog, before a 2023 financial restructuring under Canada's Companies' Creditors Arrangement Act. Its drug development assets were spun off as Reunion Neuroscience (which raised $103M Series A in 2024) while its US clinic network was acquired by Stella and its Canadian clinics by the Canadian Centre for Psychedelic Healing.

Clinical-stage natural psychedelic drug development company with publicly announced Nagoya Protocol-compliant iboga import activity from Gabon for R&D and potential therapeutic development.

The First Affiliated Hospital of Chongqing Medical University is a major academic teaching hospital in Chongqing, China, that has been a prolific clinical site for ketamine and esketamine research, with multiple randomized controlled trials spanning postpartum depression prevention, major depressive disorder combined with electroconvulsive therapy, and depression following miscarriage. Its departments of psychiatry and anesthesiology have published landmark studies demonstrating esketamine's efficacy across multiple psychiatric indications.

Miami public research university where Dr. Jerry B. Brown has taught interdisciplinary psychedelics courses since 1975, and Professor Joseph Lichter runs an Honors College Psychedelic Renaissance course covering therapeutic applications of psilocybin, MDMA, and ketamine. FIU also serves as one of 21 sites in a major national psychedelic clinical trial and hosts the Cannadelic conference — the first cannabis and psychedelics conference focused on next-generation research.

Vrije Universiteit Amsterdam (VU Amsterdam) is a major Dutch research university where neuroscientist Marco Aqil conducted the first psilocybin brain research in Amsterdam, demonstrating that psilocybin fundamentally alters visual processing by reducing cortical surround suppression. The university also hosts the Amsterdam Psychedelic Research Association (APRA) and offers an interdisciplinary honors course on the neuroscience, history, and therapeutic potential of psychedelics.

Freedom Biosciences is a Yale University spin-out developing next-generation combination therapies for treatment-resistant depression. Co-founded by Yale psychiatry chair Dr. John Krystal (CSO) and Dina Burkitbayeva (CEO, PsyMed Ventures), the company raised $10.5M seed financing in August 2022. Its lead asset FREE001 combines ketamine with temsirolimus (an mTOR inhibitor and prodrug of sirolimus) to extend the antidepressant duration of ketamine from the standard 2–7 days to approximately 14 days. FDA cleared the IND for the Phase 2a study in April 2024, and the trial (FREE001-TRD-201, n≥100) is underway.

GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Dublin, Ireland, developing novel mebufotenin (5-MeO-DMT) therapeutics for treatment-resistant depression, bipolar II disorder, and postpartum depression. Its lead asset GH001 — an inhaled mebufotenin formulation — met the primary endpoint of its Phase 2b TRD trial in February 2025 with striking results: -15.5 point MADRS reduction vs placebo (p<0.0001) and 57.7% remission vs 0%. With a single-day dosing paradigm requiring no structured psychotherapy, GH001 is positioned as a differentiated asset; Phase 3 global initiation is planned for 2026 following FDA clinical hold lift. GH002 (IV mebufotenin) completed Phase 1 in healthy volunteers.

The University Hospitals of Geneva (HUG) and the University of Geneva are leaders in clinical psychedelic research in Switzerland. HUG is the only hospital in Switzerland providing psychedelic-assisted therapy (PAT) within a clinical context, focusing on optimizing the therapeutic framework and environment for treatments involving LSD and psilocybin.

One of Europe's foremost centres for psychedelic-assisted therapy, operating within Switzerland's compassionate use framework. Under Professor Daniele Zullino, HUG treats depression and PTSD with psilocybin, LSD, and MDMA, and hosts one of five university-affiliated psychedelic research laboratories in Switzerland.

Primary registry for clinical trials in Germany, recognized by WHO as the national primary registry. Psychedelic-specific data is not provided as a dedicated public vertical.

Hospital Universitari Germans Trias i Pujol is a major public academic hospital in Badalona, Catalonia, Spain, whose Clinical Pharmacology Unit led by Dr. Magí Farré has conducted extensive human pharmacology studies on MDMA, 2C-B, and other psychedelics. The hospital's ethics committee approved the Beckley Med Foundation's ayahuasca-assisted therapy trial for complicated grief (NCT06150859), and its research institute (IGTP) lists the therapeutic use of psychedelic substances as an active research area.

Gilgamesh Pharma Inc. is the post-spinoff successor of Gilgamesh Pharmaceuticals, created in October 2025 when AbbVie acquired Gilgamesh's lead asset bretisilocin (GM-2505) for up to $1.2B. Launched with over $100M in funding and retaining the original team, Gilgamesh Pharma is advancing a pipeline of rapid-acting, durable psychiatric therapeutics including blixeprodil (GM-1020), a first-in-class oral NMDA receptor antagonist. Positive Phase 2a data for blixeprodil were announced January 6, 2026, and late-stage development is planned for 2026. The company also retains an ongoing AbbVie collaboration on non-hallucinogenic neuroplastogens.

The Global Coalition for Adaptive Research (GCAR) is a US non-profit that serves as regulatory sponsor for adaptive platform trials, including GBM AGILE (glioblastoma) and the DOD-backed M-PACT (NCT05422612), which simultaneously evaluates multiple pharmacotherapies for PTSD in active-duty service members and veterans. GCAR modernizes drug development by replacing ineffective arms with new candidates within a single master protocol.

Global anonymous survey platform with explicit psychedelic-use and microdosing self-report outputs in periodic reports.

Grand Hôpital de Charleroi (GHdC) is a large multi-site hospital system with six hospitals in Charleroi, Wallonia, Belgium, listed as a clinical research center on the European Clinical Trials Information Network. The hospital sponsors ESKEFIB (NCT04436250), a prospective randomized double-blind trial evaluating S-ketamine as a treatment for fibromyalgia, contributing to Belgium's growing ketamine clinical research infrastructure.

The Hartford HealthCare (HHC) Research Open Competition is an internal pilot grant program run by Hartford HealthCare — a large non-profit integrated health system in Connecticut — to fund investigator-initiated research at its affiliated institutions. Through this program, HHC supports a Phase I double-blind psilocybin microdosing trial at its Olin Neuropsychiatry Research Center in Hartford, investigating effects on cognition, mood and quality of life.

European catalogues that centralize metadata on real-world data sources and RWD studies for regulatory and research discoverability. These catalogues replaced older ENCePP/EU PAS register-era database surfaces.

HaEmek Medical Center is a regional public hospital in Afula, northern Israel, affiliated with the Technion's Rappaport Faculty of Medicine and operated by Clalit Health Services, serving 700,000 citizens in the Jezreel Valley. The hospital is a designated site for MAPS Israel's multi-site MDMA-assisted group therapy trial for PTSD and moral injury in veterans, contributing to Israel's pioneering psychedelic-assisted therapy research infrastructure.

The Center for Psychedelic Research at Hadassah BrainLabs in Israel is one of the premier research groups in Asia dedicated to psychedelic research. The Hadassah BrainLabs is located at the Hadassah Medical Center in Jerusalem and is affiliated with the Hebrew University.

Hadassah Medical Organization is a major non-profit academic medical center in Jerusalem, Israel, home to the Hadassah BrainLabs Center for Psychedelic Research, which develops novel psychedelic-based treatments for psychiatric disorders. The organization runs MDMA-assisted psychotherapy trials for PTSD (NCT06954025) and ketamine trials for depression (NCT05026203), and serves as the Phase 1 clinical pharmacology site for Ketamir-2, a novel oral ketamine analog.

Hammersmith Medicines Research (HMR) is the UK's largest Phase 1 clinical research organization, holding MHRA Phase 1 accreditation and a Home Office licence for controlled drug substances including psychedelics. HMR led the Phase I/IIa clinical trial of SPL026 (DMT fumarate) for major depressive disorder on behalf of Small Pharma, positioning it as a leading UK site for early-phase psychedelic medicine trials.

Harvard University hosts multiple psychedelic research initiatives including the Study of Psychedelics in Society and Culture (a $16M program), the MGH Center for the Neuroscience of Psychedelics, and the Harvard Law School POPLAR project addressing psychedelic policy reform. These programs span neuroscience, cultural studies, and legal advocacy to advance scientific and societal understanding of psychedelics.

National adverse reaction reporting and access database for marketed health products in Canada. Psychedelic relevance: Health Canada publishes psilocybin-specific clinical-trial and special-access policy notices.

The Hebrew University of Jerusalem (HUJI) is a public research university based in Jerusalem, founded in 1918 and officially opened in 1925; it is one of Israel's leading universities with multiple campuses, faculties and research centers.

Helsinki University Hospital (HUS) is Finland's largest academic medical center and the clinical partner of the University of Helsinki's Neuropsychopharmacology and Neuroscience Center laboratories, which produced the landmark discovery that psychedelics directly bind the TrkB BDNF receptor with far greater affinity than conventional antidepressants. As Finland's primary academic hospital, HUS provides the clinical infrastructure for ketamine-based treatments for suicidal depression and the planned translation of Finnish psychedelic neuroscience into human trials.

Helus Pharma is the commercial operating name of Cybin Inc., a clinical-stage biopharmaceutical company developing proprietary Novel Serotonergic Agonists (NSAs) — synthetic deuterated molecules designed to activate serotonin pathways and promote neuroplasticity. Operating across Canada, the US, UK, and Ireland, Helus holds over 100 granted patents and 250+ pending applications across its NSA portfolio. Its lead asset, HLP003 (formerly CYB003, a deuterated psilocin analogue), has received FDA Breakthrough Therapy Designation for the adjunctive treatment of major depressive disorder and is in two concurrent Phase 3 trials: APPROACH™ (topline data Q4 2026) and EMBRACE™. A key differentiator is its adjunctive design — allowing patients to continue background antidepressant medications without washout. HLP004 (a deuterated DMT analogue for intramuscular use) posted encouraging Phase 2 topline results in GAD in March 2026: 10.4-point HAM-A reduction at 6 weeks, 67% responders at 6 months, and an ~90-minute in-clinic session window. US composition-of-matter patent coverage through at least 2041.

Henan Provincial People's Hospital is a major 3A-grade hospital in Zhengzhou, China, with over 4,000 beds and a history dating to 1904; it is a key academic medical center affiliated with Zhengzhou University. Its anesthesiology department researches esketamine applications, including a trial on reducing postoperative anxiety and depression in adolescent patients.

The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) is a congressionally chartered non-profit founded in 1983 that manages research contracts and grants for the U.S. Department of Defense across global health, HIV, TBI, and PTSD. HJF is affiliated with clinical research investigating ketamine for sedation in severe traumatic brain injury — a condition at the intersection of military medicine and emerging ketamine-based therapies.

Herzog Hospital is Israel's oldest psychiatric institution (est. 1894), operating 550 beds in Jerusalem and home to the country's only dedicated inpatient unit for severe treatment-resistant depression. Researcher Dr. Uriel Heresco-Levy leads investigation of novel psilocybin combinations with NMDAR modulators for depression, including a joint patent with Hadassah BrainLabs (PCT WO 2024/052895 A1).

Homeostasis Therapeutics LLC is a Delaware company (est. 2020) that developed a novel protocol combining medically supervised ketogenic diet with ketamine infusions for treatment-resistant anorexia nervosa. In 2021–2022 they conducted a five-person IRB-approved pilot study in which four of five participants showed meaningful clinical improvement, advancing the concept of metabolic-state-dependent psychedelic therapy.

Hospital Descentralizado Dr. Marcial V. Quiroga is a public hospital in Rivadavia, San Juan Province, Argentina, serving as a key healthcare facility for the Cuyo region with active research and teaching programs. The hospital is a site for pioneering trials of sublingual 5-MeO-DMT — investigating microdoses for depression and anxiety, and higher doses for anxiety and depression in mild cognitive impairment — among the first Argentine institutions to participate in 5-MeO-DMT clinical research.

Hospital Moinhos de Vento (HMV) is a leading private non-profit hospital in Porto Alegre, Brazil, recognized as one of the country’s top healthcare institutions by national quality rankings. HMV is a reference center for ketamine treatment and co-hosts a naturalistic multicenter study (NCT05249309) with HCPA on subcutaneous ketamine infusions for depressed patients with active suicidal ideation.

Hospital Universitari Sant Joan de Reus is a Catalan university hospital operated by Grup SAGESSA in Reus, Tarragona, with a pioneering harm reduction and substance use disorders program. In 2020, ICEERS partnered with the hospital to conduct the first-ever Phase II clinical trial of ibogaine for opioid-dependent patients on methadone maintenance, making Sant Joan one of Europe’s most historically significant psychedelic research sites.

The Vall d’Hebron Research Institute (VHIR) is the biomedical research arm of Hospital Universitari Vall d’Hebron in Barcelona, one of Spain’s largest tertiary academic medical centers. VHIR researchers are investigating ketamine-assisted psychotherapy for chronic pain comorbid with major depression, exploring both psychedelic-dose intramuscular and psycholytic-dose sublingual approaches.

Hospital de Clínicas de Porto Alegre (HCPA) is a major university hospital affiliated with the Universidade Federal do Rio Grande do Sul (UFRGS) and one of Brazil’s leading academic medical centers. HCPA researchers conduct active ketamine research, including a study of ketamine combined with electroconvulsive therapy for depression and a multicenter trial of subcutaneous ketamine infusions for patients with active suicidal ideation (NCT05249309).

Huazhong University of Science and Technology (HUST) is one of China’s leading research universities in Wuhan, with Tongji Medical College and Union Hospital as major clinical research hubs. HUST researchers have conducted multiple esketamine trials — including studies on esketamine for ICU emergency intubation, postoperative neurocognitive dysfunction in elderly patients, and novel nanocarrier delivery systems to improve ketamine’s antidepressant precision.

Platform organization developing and supporting psychedelic and mental-health initiatives with philanthropic backing.

Hunan Provincial Maternal and Child Health Care Hospital is a Class-III Grade-A specialist maternity and pediatric hospital in Changsha, Hunan Province, China, founded in 1947 with over 1,050 beds and 10,000 births annually. The hospital’s anesthesiology team is a leader in esketamine obstetrics research, including a landmark BMJ randomised trial (NCT04414943) showing a single low-dose esketamine infusion after childbirth reduced major postpartum depression at 42 days by approximately three-quarters in mothers with prenatal depression.

ICEERS is a nonprofit research and policy organization focused on evidence generation, education, and legal-health support related to psychedelic and plant medicine use.

IESE Business School is a global graduate business school at the University of Navarra, based in Barcelona, that contributes to psychedelic research through the PsyPal consortium. As part of the first EU-funded psychedelic clinical study (€6.5M, 19 partners), IESE hosts design thinking workshops and brings expertise in health economics, organizational implementation, and stakeholder strategy to support the psilocybin palliative care trial.

French National Institute of Health and Medical Research (INSERM), a national public biomedical research organization with active discourse and research engagement on psychedelic medicine.

European doctoral network training the next generation of psychedelic therapy researchers through coordinated cross-institution programs.

Commercial real-world data products and linked evidence assets used in life sciences research and regulatory support.

Primary clinical trial registry with global participation and searchable records including psychedelic-related studies; no dedicated psychedelic-specific product surface.

Icahn School of Medicine at Mount Sinai is a leading US academic medical institution home to the Parsons Research Center for Psychedelic Healing, which runs rigorous clinical trials of MDMA- and psilocybin-assisted therapies for PTSD and trauma in veteran and civilian populations.

Idorsia Pharmaceuticals Ltd. is a Swiss publicly traded biopharmaceutical company (spun out of Actelion in 2017) focused on developing medicines for high-unmet-need conditions, with products including the dual orexin receptor antagonist daridorexant (Quviviq) for insomnia. Idorsia is a participating organization in the U.S. Department of Defense PTSD Adaptive Platform Trial, which evaluates multiple therapeutic interventions — including the intranasal ketamine compound SLS-002 — for veterans with treatment-resistant PTSD.

Imelda Hospital is a Catholic general hospital in Bonheiden, in the Antwerp province of Belgium, offering a full range of acute care and specialist services across approximately 550 beds. The hospital has contributed to clinical research on ketamine for the management of acute brain injury patients.

The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).

Dr. Michael Koslowski leads research at Aix-Marseille University investigating the therapeutic potential of psychedelics, particularly LSD, for treating mental illnesses such as anxiety and depression. His work emphasizes the integration of neuroscience and clinical applications.

This stakeholder record appears to be a data parsing artifact where only the corporate suffix 'Inc.' was captured without the full organization name. It is listed as a collaborator in two US psilocybin research trials: a VA-sponsored Phase I/II study on psilocybin for depression in spinal cord injury veterans (NCT07251491) and a group retreat psilocybin therapy trial for cancer patients at Fred Hutch/UW Cancer Consortium (NCT07336238).

Incannex Healthcare is an Australian clinical-stage pharmaceutical company (ASX: IHL, Nasdaq: IXHL) developing psilocybin-assisted therapy and novel fixed-dose combinations. Their lead psychedelic programme PSX-001 is synthetic psilocybin combined with a proprietary psychotherapy protocol for Generalised Anxiety Disorder (GAD) — the world's first RCT of psilocybin-assisted therapy for a primary anxiety disorder. The Phase 2 PsiGAD1 trial (n=73) at Monash University delivered strongly positive results in August 2025: HAM-A reduction of 12.8 vs 3.6 points for placebo (p<0.0001), with 44% clinical response vs 11% for placebo. FDA cleared a Phase 2b IND (PsiGAD2) in August 2024 for US and UK sites; MHRA Clinical Trial Authorisation also granted. Incannex entered 2026 well-funded (~$70M cash) and with PsiGAD2 site start-up underway. The company also has non-psychedelic programmes: IHL-42X (dronabinol + acetazolamide for OSA, Phase 2/3, FDA Fast Track) and IHL-675A (CBD + hydroxychloroquine for rheumatoid arthritis, Phase 2).

The Inner Mongolia Autonomous Region Mental Health Center is a government-affiliated regional psychiatric institution in Hohhot, China, affiliated with the School of Mental Health at Inner Mongolia Medical University. The center has participated in clinical research on esketamine for treating depressive episodes with suicidal ideation in patients with mood disorders.

İnönü University is a Turkish state research university in Malatya, with a medical faculty conducting clinical investigations across anesthesiology, psychiatry, and surgery. The university's departments have studied ketamine in obstetric anesthesia, ketamine augmentation of electroconvulsive therapy for psychiatric conditions, and cardiac safety during ECT.

Insel Gruppe AG operates Inselspital (Bern University Hospital), one of Switzerland's five dedicated centers for psychedelic medicine research and among the largest university hospital groups in Europe. The hospital's psychiatry department runs the HaD-PET neuroimaging study on harmine and DMT, and has published real-world outcomes of LSD- and psilocybin-assisted psychotherapy in routine clinical care.

The Institute for Integration of Medicine & Science (IIMS) at UT Health San Antonio is the institution's NIH-funded Clinical and Translational Science Award hub, supporting multi-disciplinary translational research across South Texas. The institute has been involved in a clinical trial combining esketamine with prolonged exposure therapy for post-traumatic stress disorder.

The Institute of Psychology of the Polish Academy of Sciences is a Warsaw-based research institute that conducts basic and applied research across psychological sciences (cognitive, developmental, clinical, social and related fields).

Instituto Nacional de Canciología de México (INCan) is Mexico's federal national cancer institute in Mexico City, operating as a leading oncology specialty hospital and research center. The institute has participated in a clinical trial examining ketamine versus placebo for treating major depression in patients with advanced cancer.

A Brazilian non-profit research institute (founded 2011) based in São Paulo that conducts research and education on psychedelic-assisted psychotherapy and trains health professionals for related clinical research.

Instituto Superior Técnico (Técnico Lisboa) is the school of engineering, science and technology of the University of Lisbon, offering undergraduate and postgraduate programs and conducting research in engineering, architecture, science and technology. Founded in 1911, it is Portugal’s largest and most reputed engineering school.

The Instituto do Cérebro (Brain Institute, ICe) is an academic research institute of the Federal University of Rio Grande do Norte (UFRN) in Natal, Brazil, focused on neuroscience research, education and public outreach. It hosts the postgraduate Program in Neurosciences (PGNeuro) and supports related research groups and events.

The Integrative Psychedelic Clinic at Lev Ha Sharon is the first public psychedelic clinic in Israel. It participates in multicenter studies on MDMA-assisted psychotherapy, specifically focusing on its efficacy for early childhood trauma and PTSD.

The Integrative Psychiatry Institute (IPI), co-founded by Will Van Derveer MD and Keith Kurlander, is a leading US psychedelic-assisted therapy training organization that has trained over 2,200 healthcare providers in 300-hour programs covering ketamine, MDMA, and psilocybin. IPI's psilocybin track was among the first approved by the Oregon Health Authority, and the institute collaborates with the Usona Institute and ASKP³ to develop evidence-based curricula.

ICEERS (International Center for Ethnobotanical Education, Research and Service) is a nonprofit supporting ethnobotanical research, policy engagement, and community-informed programming around ayahuasca, iboga, and related plant medicines.

The International Society for Research on Psychedelics (ISRP) is a professional scientific society that connects researchers across disciplines to advance rigorous psychedelic science, collaboration, and dissemination.

Istanbul Training and Research Hospital is a major public academic medical center in Istanbul, Turkey, affiliated with the Istanbul Provincial Health Directorate and serving as a regional training hub for medical residents and specialists across multiple disciplines. The hospital has conducted clinical research on subanesthetic ketamine doses for postoperative mood improvement in gynecological surgical patients.

Istituto Superiore di Sanità (ISS) is Italy's National Institute of Health, the country's principal technical and scientific public body for biomedical research, public health surveillance, and regulatory advisory functions. The institute has participated in pharmacological research on designer psychoactive substances including methylone, an MDMA analogue, contributing to Italy's evidence base for novel psychoactive substance regulation.

The Jagiellonian University (Uniwersytet Jagielloński) is a public research university in Kraków, Poland, founded in 1364; it is the oldest university in Poland and one of the oldest universities in Europe.

Janssen Korea Ltd. is the South Korean affiliate of Janssen Pharmaceuticals, the pharmaceutical subsidiary of Johnson & Johnson. The company markets esketamine nasal spray (Spravato) in South Korea following regulatory approval for treatment-resistant depression and major depressive disorder with acute suicidal ideation.

Pharmaceutical sponsor operating SPRAVATO REMS restricted-distribution controls for supervised administration, site certification, and patient enrollment in the US market.

Janssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.

Jiangsu HengRui Medicine Co., Ltd. is one of China's largest publicly listed pharmaceutical companies, specializing in innovative drugs across oncology, anesthesia, and metabolic diseases. The company has developed HR071603, a proprietary ketamine nasal spray candidate, which entered Phase I clinical evaluation in healthy subjects.

A research center within Johns Hopkins University (School of Medicine) that conducts scientific studies on psychedelic compounds, their effects on brain function and consciousness, and their therapeutic potential for mental health conditions.

The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.

Johnson & Johnson is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Journey Colab is a US psychedelic pharmaceutical company developing synthetic mescaline hydrochloride for alcohol use disorder (AUD). Founded in 2020, the company has raised $30.7M from investors including Sam Altman, Apollo Projects, and Drew Houston. Journey Colab has dedicated 10% of its founding equity to a Reciprocity Trust supporting Indigenous communities from which mescaline knowledge originates. The company is partnering with All Points North (APN) for an FDA-authorised Phase 2 clinical trial.

The Juvenile Bipolar Research Foundation is a US non-profit dedicated to funding scientific research into bipolar disorder in children and adolescents. The foundation has supported clinical research on intranasal ketamine for pediatric bipolar disorder and neurobiological studies of ketamine's effects in children and adults with bipolar disorder.

KGK Science Inc. is a Canadian contract research organization (CRO) based in London, Ontario, specializing in clinical trial execution across natural health products, novel therapeutics, and medical devices. The company has served as a trial management partner on psilocybin studies for treatment-resistant PTSD and behavioral and cognitive symptoms in adults with Fragile X Syndrome.

Karolinska Institutet is Sweden's largest medical university and a leading European hub for psychedelic research, with the Centre for Psychiatry Research led by Prof. Johan Lundberg conducting PSIPET — Sweden's first RCT of psilocybin for major depressive disorder. The institute participates in the Nordic Network for Psychedelic Science and launched a doctoral course in psychedelic science in 2025.

Neurotechnology company developing non-invasive brain measurement systems with applications in psychiatry and published psychedelic-adjacent ketamine research collaborations.

Ketabon GmbH is a Munich-based joint venture between HMNC Brain Health and Develco Pharma developing KET01, an oral prolonged-release (PR) racemic ketamine tablet for TRD. Founded in 2022, Ketabon's strategy centres on enabling at-home, unsupervised ketamine therapy by dramatically reducing dissociation and cardiovascular side effects through slow drug release. Two Phase 2 studies are complete: KET01-01 (UZH investigator-initiated PoC, ~zero dissociation, trend toward MADRS improvement at 240mg) and KET01-02 (n=122, 29 sites across Germany/Poland/Czech Republic, 240mg arm showed statistically significant rapid-onset MADRS improvement at Day 4 and 7, sustained through Day 21 and 4-week follow-up; primary Day 21 endpoint missed due to high placebo response). A head-to-head study vs. Spravato (esketamine nasal spray) confirmed significantly lower dissociation for KET01. Post-hoc analysis presented at ECNP Amsterdam (October 2025) demonstrated that KET01's antidepressant effect is dissociation-independent, strengthening the regulatory case for home use. Phase 3 initiation was targeted for 2025; IP exclusivity through 2039.

The Ketamine Research Institute is a US-based clinical research organization developing precision medicine approaches to ketamine infusion therapy, studying optimized dosing protocols to treat depression and offering clinician training in evidence-based ketamine practice.

Khyber Medical University (KMU) is a public medical research university in Peshawar, Khyber Pakhtunkhwa, Pakistan, operating multiple affiliated teaching hospitals and health sciences colleges across the region. The university's medical faculty has contributed to clinical research on anesthetic and sedative agents including ketamine in perioperative and psychiatric contexts.

King George's Medical University (KGMU) is a public medical university and large teaching hospital in Lucknow, Uttar Pradesh, India, established in 1905; it offers undergraduate, postgraduate and research programs in medicine, dentistry, nursing and allied health sciences.

The Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.

One of the longest-operating ketamine therapy networks in the United States, Klarisana runs five intramuscular ketamine clinics across Texas and Colorado—founded in San Antonio in 2015 and a founding member of the American Society of Ketamine Physicians. The practice participated in clinical research on ketamine infusion therapy for PTSD in paramedics, having administered nearly 20,000 IM ketamine sessions annually by 2022.

Kuleon Bioscience is a Seattle-based drug discovery company leveraging AI-based technology to identify novel serotonergic drugs for neuropsychiatric diseases. The company specialises in biased serotonin receptor ligands — including the world's first known trifunctional 5-HT2C agonist / 5-HT2A antagonist / 5-HT2B antagonist — designed to deliver therapeutic efficacy without hallucinogenic or cardiotoxic side effects. Its lead programme KB-128 targets alcohol use disorder and is supported by a $2 million NIAAA grant.

An atai Life Sciences subsidiary and Columbia University spinout, Kures developed KUR-101—a deuterated mitragynine derivative from the kratom plant—as a safer opioid receptor modulator for acute pain and opioid use disorder, with a second asset KUR-002 targeting depression. The Phase 1 trial of KUR-101 in healthy adults demonstrated safety and tolerability with no severe adverse events, advancing a kratom-derived mechanism distinct from conventional opioids.

Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.

A Los Angeles ketamine treatment and functional medicine clinic that pioneered at-home sublingual ketamine microdosing programs, Limbic Medical published research in the Journal of Psychedelic Studies showing 100% improvement in anxiety and 96% improvement in PTSD among frontline healthcare workers treated with daily low-dose sublingual ketamine during the COVID-19 pandemic. The clinic integrates ketamine infusions, hydration therapies, and telemedicine-based microdose programs under its founding physician.

Liverpool John Moores University (LJMU) is a public university in Liverpool, England, United Kingdom, offering undergraduate and postgraduate teaching and research across a wide range of disciplines.

Canadian psychedelic biotech developing conjugated psilocin formulations for treatment-resistant conditions. Spun out its proprietary Conjugated Psilocin™ technology to Cynaptec Pharmaceuticals in April 2025 via an $8.46 million financing round. Lead programme L-130 targets cluster headache disorder.

A Seventh-day Adventist university and academic health system in Loma Linda, California with a medical school, research hospital, and multiple health sciences schools; Loma Linda University researchers have investigated the neurophysiological mechanisms of ketamine in the prefrontal cortex and conducted a clinical trial of low-dose ketamine infusion for treatment-resistant depression.

Lophora ApS is a Danish biotech developing next-generation selective 5-HT2A receptor agonists for psychiatric disorders. Their lead compound LPH-5, a novel cyclized phenethylamine, is in Phase 1 trials at Biotrial in Rennes, France. LPH-5 shows exceptional 5-HT2A selectivity and can produce antidepressant effects at sub-psychedelic doses. Secondary candidate LPH-48 is being explored for alcohol use disorder.

Louisiana State University Health Sciences Center in New Orleans (LSU Health New Orleans) is an academic health sciences center in New Orleans, Louisiana, offering medical, dental, nursing, public health, allied health, and graduate education alongside clinical services and biomedical research.

The non-profit research arm of Harbor-UCLA Medical Center in Torrance, California, the Lundquist Institute hosted Dr. Charles Grob's landmark 2004–2008 pilot study—one of the first modern psilocybin trials for anxiety in advanced-stage cancer patients, published in Archives of General Psychiatry (2011). The Institute subsequently received $1.75M from the Steven & Alexandra Cohen Foundation and a Samberg Foundation gift to co-lead a new multi-site psilocybin palliative care trial alongside NYU's Dr. Anthony Bossis.

A leading medical research university in Lviv, western Ukraine, founded in 1784 and one of the oldest medical schools in Eastern Europe; Lviv National Medical University researchers have studied ketamine, stellate ganglion block (SGB), and combination approaches for treating traumatic brain injury (TBI)—research carrying particular relevance given Ukraine’s frontline experience with combat-related neurotrauma.

One of the world’s leading comprehensive cancer centers, affiliated with UT Health Houston, MD Anderson Cancer Center has emerged as a site for landmark psychedelic research; the institution is conducting psilocybin-assisted psychotherapy trials in patients with advanced cancer and co-investigates NeuroGuard—a novel trial exploring psilocybin to prevent chemotherapy-induced peripheral neuropathy.

UK clinical research organization and site operator focused on complex CNS and psychedelic studies, with dedicated psychedelic testing suites and early-to-late phase delivery capabilities.

The Amsterdam-based European subsidiary of MAPS (Multidisciplinary Association for Psychedelic Studies), MAPS Europe B.V. was established in 2018 to advance MDMA-assisted psychotherapy through EMA-regulated Phase 2 and Phase 3 clinical trials for PTSD across Europe. The organization ran the first multi-site European MDMA/PTSD Phase 2 open-label study with sites in London, Berlin, Lisbon, and others, and trained therapists from 14 countries.

The METIV Israel Psychotrauma Center is a leading authority in trauma treatment and research. The center is involved in exploring MDMA-assisted therapy for PTSD, aligning with a broader mission to develop advanced treatment methods for trauma-related conditions exacerbated by conflict.

UK safety reporting program for medicine and device adverse events. Psychedelic relevance: UK has active policy and trial activity, while public MHRA records indicate no authorized psilocybin medicinal product yet.

European nonprofit research and implementation organization that organizes the INSIGHT Conference and allied public/professional events.

MSICS Pharma is an Israeli biotechnology company that operates a GMP production facility for naturally-sourced psilocybin. Their lead candidate MSX-06, a naturally-sourced psilocybin formulation, is in Phase 2 clinical development targeting treatment-resistant depression and obsessive-compulsive disorder.

While Maastricht University may not have a single dedicated psychedelic research group, various researchers at the university are investigating the effects of psychedelics. Early research exploring psychedelics at Maastricht focused on the dangers of MDMA. Now, research into the effects of microdosing is being led by Dr Kim Kuypers. Other research ongoing at the university is investigating cannabis as well as novel psychoactive substances (NPS). Maastricht is collaborating on research with the Beckley Foundation as well as Silo Pharma.

Macquarie University is a public research university located in Macquarie Park, Sydney, New South Wales, Australia. Founded in 1964, it is known for strong industry links and a large suburban campus northwest of the Sydney CBD.

MADoPA (Maintien en Autonomie à Domicile des Personnes Âgées) is a French expert centre and Living Lab founded in 2008 in Troyes, specializing in the co-design and socio-anthropological evaluation of technologies and services supporting elderly and disabled people’s independence at home, affiliated with EIT Health since 2014. As a PsyPal consortium partner, MADoPA leads the Public and Patient Involvement Workgroup (WP4), contributing qualitative research and ethnographic methodologies to the EU-funded €6.5M psilocybin palliative care trial.

Thailand’s highest-ranked research university, comprising 17 faculties including the Faculty of Medicine Siriraj Hospital and Ramathibodi Hospital in Bangkok; Mahidol University researchers have conducted a randomized controlled pilot trial of three consecutive daily IV ketamine infusions for treatment-resistant depression and published multiple studies and reviews on ketamine and esketamine efficacy and safety in major depressive disorder.

Marvel Biosciences is a Calgary-based clinical-stage biotechnology company pursuing a 'drug redevelopment' strategy to create synthetic derivatives of approved drugs with improved therapeutic profiles. Its lead candidate MB-204, a fluorinated derivative of the adenosine A2a receptor antagonist Istradefylline, is advancing through IND-enabling pre-clinical studies targeting autism spectrum disorder, Rett syndrome, and depression, with Phase 1 trials expected to begin in Australia.

The Center for the Neuroscience of Psychedelics aims to better understand how psychedelics can be used to improve the treatment of mental illnesses. The core mission of the center is to understand exactly how psychedelics enhance the brain's capacity for change—or neuroplasticity—to optimize current treatments and render the term treatment resistant obsolete.

Multi-campus academic medical center and one of the most recognized healthcare institutions in the world. Mayo Clinic researchers have published evidence reviews on psilocybin-assisted therapy for depression, anxiety, and alcohol use disorder, and have collaborated on ketamine clinical trials — including a biomarker study with the University of Michigan — for treatment-resistant depression.

A leading Canadian research university in Montreal, Quebec, McGill pioneered the “Montreal Model”—an integrative biomedical-psychedelic approach to ketamine-assisted psychotherapy for severe treatment-resistant depression developed over 6 years and 500+ ketamine treatments. The team’s MUSIK randomized trial demonstrated that emotional and mystical ketamine experiences within a structured therapeutic environment drive more sustained antidepressant improvements, including in ketamine vs. ECT comparison trials.

A Canadian research university in Hamilton, Ontario, McMaster University houses the Centre for Medicinal Cannabis Research and an expanding psychedelic science program including the McMaster Psychedelic Research Society; the university is sponsoring the PSI_CUD trial—a Phase 2 proof-of-concept study of psilocybin-assisted psychotherapy (two 25mg doses within an 8-week Motivational Enhancement Therapy framework) for cannabis use disorder.

Harvard Medical School-affiliated psychiatric hospital and one of the leading mental health research institutions in the United States. Operates a dedicated Ketamine Service for treatment-resistant depression and is actively expanding into psilocybin research for depression, bipolar disorder, and other psychiatric conditions.

The Medical College of Georgia (MCG) is the medical school of Augusta University, a public medical school based in Augusta, Georgia, United States, that educates MD students and operates multiple campuses and clinical training sites across the state.

The Medical College of Wisconsin (MCW) is a private health sciences university and medical school based in Milwaukee, Wisconsin. It offers medical, pharmacy, and graduate programs and is clinically affiliated with Froedtert Hospital and Children’s Hospital of Wisconsin.

Hannover Medical School (Medizinische Hochschule Hannover, MHH) is a research-intensive university medical centre and teaching hospital located in Hannover, Germany. It provides medical and dental education, conducts clinical and biomedical research (notably in transplantation, infection/immunity and biomedical technology), and operates a large university hospital.

Leading Austrian medical university in Innsbruck. Researchers here have investigated the structural biology of psilocybin-biosynthesizing enzymes with the aim of optimizing sustainable psilocybin production, while also contributing to clinical research as European psychedelic frameworks evolve.

The Medical University of Gdańsk is Poland's leading academic medical institution, with its Department of Psychiatry running one of the country's most active research programs on ketamine and esketamine for treatment-resistant depression and bipolar disorder.

The Medical University of South Carolina (MUSC) is a public academic health sciences center in Charleston, South Carolina, founded in 1824. It comprises multiple colleges (Medicine, Dental Medicine, Health Professions, Nursing, Pharmacy, and Graduate Studies) and provides education, biomedical research, and clinical care across the state.

The Medical University of Vienna (MedUni Vienna) is Austria’s largest medical university, a leading centre for medical education and research closely affiliated with the Vienna General Hospital (AKH).

New Zealand pharmacovigilance infrastructure operated through Medsafe and CARM for adverse-reaction reporting, analysis, and signal monitoring. Public psychedelic-specific dashboards are limited; this profile is included as core safety infrastructure.

Melt Pharmaceuticals is a US specialty pharmaceutical company — carved out from Harrow, Inc. in 2019 and subsequently re-acquired — that developed MELT-300, a sublingual fast-dissolving tablet combining ketamine (50 mg) and midazolam (3 mg) for opioid-free procedural sedation using Catalent's Zydis® technology. The company reported positive Phase 3 topline results for cataract surgery sedation in November 2024, positioning MELT-300 for FDA regulatory submission.

MercyOne Des Moines Medical Center is a 622-bed hospital in Des Moines, Iowa, certified as a Level II Area Trauma Care Facility and part of the Trinity Health system. The center served as the primary site for a clinical study of antidepressant ketamine administered in the emergency department for patients presenting with severe depression or suicidal ideation (NCT04266288), and subsequently integrated Spravato (esketamine) nasal spray into its behavioral health services.

Mike O'Callaghan Military Medical Center is the primary military hospital at Nellis Air Force Base in Las Vegas, Nevada, operated by the 99th Medical Group and serving active duty personnel and their families through TRICARE. The center sponsored the CHECK Trial — a multicenter, randomized, double-blind study comparing sub-dissociative ketamine against prochlorperazine for emergency department headache treatment, published in Annals of Emergency Medicine in 2018.

MindBio Therapeutics is a clinical-stage biotechnology company developing MB22001, a proprietary titratable form of LSD designed for take-home microdosing. The company's Phase 2B trials in major depressive disorder and advanced-stage cancer distress have reported strong antidepressant effects, with Phase 2a data showing a 72% reduction in depressive symptoms and 58% remission at six months. MindBio is listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange.

Canadian drug discovery company focused on next-generation psilocybin and DMT analogues, acquired by Otsuka Pharmaceutical in October 2023 for approximately C$80 million. Lead compound MSP-1014, a novel psilocin prodrug, received MHRA approval for a Phase 2 clinical trial in the UK for major depressive disorder.

Clinical-stage AI neuroengineering platform company focused on designing psychoactive effect profiles and developing next-generation neuropsychiatric programs with psychedelic relevance.

The Minneapolis VA Health Care System (MVAHCS) is a Veterans Affairs medical center and network of clinics in Minneapolis, Minnesota, that provides clinical care, research, and training for veterans and maintains an academic affiliation with the University of Minnesota Medical School.

Public university in St. Joseph, Missouri, home to Dr. Christine Ziemer's pioneering undergraduate courses in psychedelic-assisted psychotherapy and transpersonal psychology covering psilocybin, LSD, MDMA, ketamine, and ayahuasca research and therapeutic applications. Dr. Ziemer founded the Psychedelic Educators Network, serves as executive director of the Psychedelic Society of Kansas City, and supports harm reduction through the Fireside Project and Zendo Project, making Missouri Western a notable hub for Midwestern psychedelic education.

Led by Prof. Gregor Hasler, the Molecular Psychiatry Lab investigates the effects of psychedelic substances like LSD, psilocybin, and MDMA on brain function and neuroplasticity. Their work aims to understand how these substances can reorganize brain function and enhance neuroplasticity, leading to long-lasting therapeutic benefits for psychiatric disorders.

The Clinical Psychedelic Lab, led by Dr. Paul Liknaitzky, conducts robust clinical trials exploring the efficacy and safety of psychedelic-assisted therapies for various mental health conditions within the Australian healthcare context.

The Center for Psychedelic Psychotherapy and Trauma Research located at Mount Sinai and the James J. Peters Department of Veterans Affairs examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms. The Parsons Research Center for Psychedelic Healing has also recently opened at the Icahn School of Medicine at Mount Sinai.

MycoMedica Life Sciences PBC is a public benefit corporation developing low-dose psilocybin medicines for psychiatric and neurological disorders. Their lead candidate MLS101 is in Phase 1 clinical development, with PMDD as the lead indication and OUD and OCD as additional targets. Based in Shelton, Washington.

Mycrodose Therapeutics is a San Diego-based biotech developing advanced drug delivery systems for psychedelic and controlled-substance therapeutics. One of only a few companies with DEA Schedule I research licences covering psilocybin, LSD, MDMA, and DMT, the company has demonstrated in vitro delivery of psilocin through human skin using a proprietary transdermal patch technology. A second programme involves an oral mucosa delivery system for ketamine targeting cancer-related mucositis. Mycrodose has completed an oversubscribed private placement to expand its patent portfolio.

Canadian biotech using AI-assisted drug discovery at the University of Alberta to develop novel psilocybin and MDMA analogues for mental health and addiction treatment. Pipeline compounds MYCO-003 through MYCO-007 represent a library of psychedelic-inspired molecules at preclinical stage.

NHS Grampian is the National Health Service health board serving northeast Scotland — including the city of Aberdeen and surrounding Aberdeenshire — providing acute hospital care through facilities such as Royal Cornhill Hospital and Aberdeen Royal Infirmary. The organisation led the KANECT randomised controlled trial comparing ketamine against propofol as ECT anaesthetic for major depression, conducted at Royal Cornhill Hospital between 2011 and 2013 and published in the British Journal of Psychiatry in 2017.

NRx Pharmaceuticals is a US-based NASDAQ-listed biopharmaceutical company developing NRX-100, a proprietary preservative-free formulation of intravenous ketamine, for the acute treatment of suicidal ideation in patients with depression including bipolar depression. Unlike most commercially available ketamine products, NRX-100 omits the benzethonium chloride preservative, whose safety profile in repeated dosing has not been established. Rather than running a traditional Phase 3 trial, NRx is pursuing NDA approval based on already-completed government-funded controlled trials (demonstrating 55–63% response/remission vs 30–31% for comparators), expanded access data, and — in a regulatory first — de-identified real-world evidence from over 70,000 US patients treated with IV or intranasal ketamine, licensed and submitted to the FDA in January 2026. The FDA granted Fast Track Designation to NRX-100 for suicidal ideation in depression in August 2025, and the company has applied for a Commissioner’s National Priority Voucher (CNPV) review, which could reduce review time to 1–2 months. The NDA filing is underway, with PDUFA date expected 2025–2026. A parallel generic pathway (KETAFREE™ ANDA) targets the broader ketamine market, with a Q2 2026 GDUFA date anticipated.

NWTraumatherapies is a Bozeman, Montana-based network organisation directed by mechanotherapist Ross Allison that developed the Northwest Therapies Trauma Psilocybin Study (NWTTPS), a compassionate use protocol exploring enhanced psilocybin microdosing for chronic trauma conditions including PTSD, depression, and long COVID. The study (NCT05042466) lists Imperial College London, the WHO, and Johns Hopkins University as scientific collaborators and employs a multi-week microdosing protocol with therapist-supervised integration.

NYU Langone Health’s Center for Psychedelic Medicine (NYU CPM) conducts health-focused translational research, education, and training on the therapeutic use of psychedelic drugs across psychiatry, medicine, and preclinical science. It supports clinical trials and a research training program to develop investigators and clinicians in the field.

NYU Grossman School of Medicine is New York University's medical school and a core academic unit of NYU Langone Health. It provides MD and other medical education, conducts biomedical research, and delivers clinical care in the United States.

Home to the NYU Langone Center for Psychedelic Medicine, one of the world's leading academic institutions in psychedelic research. Has conducted landmark psilocybin trials for smoking cessation, alcohol use disorder, and depression in cancer patients, spearheaded by Dr. Michael Bogenschutz and colleagues.

Nanfang Hospital (南方医院) is a Grade-A tertiary hospital affiliated with Southern Medical University, founded in 1941 in Guangzhou, China, with 3,601 beds and over 3.25 million outpatient visits annually, consistently ranked among China’s top 20 hospitals by Fudan University. The hospital’s Department of Anesthesiology has investigated the effects of low-dose esketamine on postoperative delirium prevention in high-risk elderly surgical patients in the ELEMENT trial, contributing to a growing body of Chinese RCT evidence on esketamine’s neuroprotective properties.

Naropa University is a Boulder, Colorado Buddhist-inspired private university founded in 1974 that emerged as a national leader in psychedelic education through its Naropa Center for Psychedelic Studies (NCPS) and undergraduate Psychedelic Studies Minor. The NCPS separated in late 2024 to become the independent Memoru Center for Visionary Healing Arts, while Naropa continues to offer its contemplative-approach psychedelic studies minor and transpersonal psychology graduate programs.

The Nathan S. Kline Institute for Psychiatric Research (NKI) is a research institute operated by the New York State Office of Mental Health in Rockland County, New York. It conducts biological, clinical, and computational research on psychiatric disorders and collaborates with academic partners such as New York University.

The National Center for PTSD (NC-PTSD) is a US Department of Veterans Affairs centre of excellence for research, education, and training on post-traumatic stress disorder, operating across seven VA medical centre sites with a focus on evidence-based assessment and treatment. The Centre has supported mechanistic ketamine research in military and veteran populations, including an investigation of AMPA receptor blockade on ketamine’s anti-suicidal effects relevant to veteran mental health crises.

U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.

The National Institute of Neurology and Neurosurgery (INNN; Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez) is a Mexican federal specialist hospital and research institute in Mexico City dedicated to the diagnosis, treatment, and study of neurological and neurosurgical conditions. The INNN has been a centre for ketamine research in treatment-resistant depression, conducting trials evaluating intravenous ketamine dosing regimens for patients unresponsive to standard antidepressant therapy.

U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.

The National Network of Depression Centers (NNDC) is a US non-profit consortium of academic medical centres united to advance the prevention, diagnosis, and treatment of mood disorders through collaborative research, clinical programmes, and policy advocacy, with member institutions spanning more than 25 major academic health systems. The NNDC supported the BIO-K study, an open-label biomarker development trial investigating intravenous ketamine for non-psychotic unipolar major depression and bipolar I/II depression.

The National University of Natural Medicine (NUNM) is a Portland, Oregon-based accredited institution offering graduate programmes in naturopathic medicine, integrative medicine, and classical Chinese medicine, with a research focus on evidence-based natural health approaches. NUNM co-sponsored the Optimizing Microdosing and Meditation (OMM) trial, studying whether combining psilocybin microdosing with structured mindfulness meditation practice produces synergistic improvements in psychological wellbeing.

The National University of Singapore (NUS) is a comprehensive, research-intensive public university in Singapore, founded in 1905. It is a leading global university based in Singapore, known for a wide range of undergraduate and graduate programs and strong research output.

The National and Kapodistrian University of Athens (NKUA; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών) is Greece’s oldest and largest university, founded in 1837, with one of Southern Europe’s largest medical schools conducting both basic science and clinical research. NKUA researchers have investigated the co-administration of lidocaine and ketamine as an analgesic protocol for opioid-refractory chronic cancer-related pain, exploring combination approaches as alternatives to escalating opioid therapy.

Nationwide Children's Hospital is a leading pediatric academic medical center in Columbus, Ohio, operating one of the largest sickle cell disease programs in the state and providing comprehensive care for pediatric hematology, psychiatry, and pain management. The hospital has conducted research on IV ketamine as an adjunct for sickle cell vaso-occlusive pain crises and suicidal ideation in adolescents.

Naval Medical Center Camp Lejeune is the primary U.S. military hospital serving Marine Corps Base Camp Lejeune in Jacksonville, North Carolina, operating ACGME-accredited residency programs in family medicine and psychiatry. The center sponsored NCT04260607, a randomized controlled trial of IV ketamine versus placebo for rapid stabilization of acutely suicidal patients presenting to the emergency department.

Negev Labs is a biotech company-building platform founded in 2022 and headquartered in Fort Lee, New Jersey, dedicated to advancing neuroplastogens — non-hallucinogenic compounds that promote neuroplasticity and cellular resilience. The company operates through R&D partnerships with Hadassah Brain Labs Center for Psychedelic Research in Jerusalem, a licensing agreement with the Alexander Shulgin Research Institute (ASRI), and acquired Beckley Psytech's ophthalmology program, targeting psychiatry, neurodegeneration, and retinal degeneration.

National pharmacovigilance centre for the Netherlands supporting adverse drug reaction reporting, signal detection, and patient-reporting channels. Public psychedelic-specific evidence views are limited; this profile is included as core safety infrastructure.

Neurala Biosciences is a Melbourne-based clinical-stage biotech developing second-generation DMT–harmala alkaloid neuromedicines for mental health and addiction. Emerging from over a decade of research at the University of Melbourne, their Phase 1 proof-of-concept study was published in Scientific Reports (2025). Lead candidate NBX-100 targets substance use disorder; NBX-200 targets depressive illness.

NRx Pharmaceuticals (formerly NeuroRx, Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing a sequential therapy for suicidal bipolar depression: NRX-100 (preservative-free IV ketamine) for acute stabilization followed by NRX-101 (D-cycloserine/lurasidone) for maintenance, both holding FDA Breakthrough Therapy Designation. The company filed an NDA with the FDA for NRX-100 in 2024 in support of accelerated approval.

Neurocentrx Pharma Limited is a private Scottish clinical-stage company developing NRCx-201 (Keticap) — an immediate-release, abuse-deterrent oral ketamine capsule paired with proprietary digital prescription safety software for regulated clinic-to-home care. Founded in 2013 by CEO Carmel Reilly at the University of Edinburgh, the company raised ~$6.15M total including a September 2025 seed extension (~$5M) led by the Wellcome Trust to fund a Phase 2 proof-of-concept trial in treatment-resistant bipolar depression (planned Q1 2026). Phase 1 (King's College London, EudraCT 2019-001019-22, n=18, 40–240mg) completed early 2023 with positive results: well-tolerated at all doses, no SAEs, PK comparable to IV/intranasal esketamine, no cognitive impairment. MHRA has indicated NRCx-201 is suitable for direct Phase 3 submission for TRD (company plans Phase 2 first). Key investors: Wellcome Trust, Neo Kuma Ventures, O2h Ventures, Equity Gap.

Neurological Associates of West Los Angeles (NAOWLA) is a private neurology and psychiatry group practice in Santa Monica, California, founded in 1981 and affiliated with the UCLA Department of Neurology. The practice sponsored NCT04205890, a clinical trial investigating intravenous ketamine effects on functional neuroanatomy in treatment-resistant depression via pre/post brain imaging.

State-funded psychiatric research institute affiliated with Columbia University, located in New York City. A key site for psilocybin clinical trials including the landmark COMP360 study for treatment-resistant depression, and conducts broader research on LSD, DMT, ayahuasca, and ketamine through Columbia's Depression Evaluation Service.

The Center for Psychedelic Medicine at NYU Langone Health is directed by Dr. Michael Bogenschutz and performs health-focused research across the translational spectrum, from basic science to large-phase clinical trials. The center has three transdisciplinary areas of focus: psychiatry, medicine, and preclinical research. Currently, the team is actively investigating clinical applications for various psychedelic compounds, leading robust studies on psilocybin-assisted therapy for alcohol use disorder, major depression, and advanced cancer-related psychiatric distress.

Physician-led New Zealand clinical research organization with early-phase specialization and multi-site operations; identified in partner disclosures as experienced in psychedelic studies.

Northwell Health is New York's largest health system with 28 hospitals, which opened the Center for Psychedelics Research and Treatment (CPRT) at Zucker Hillside Hospital in 2026 to study psilocybin for anxiety disorders, MDMA for schizophrenia negative symptoms, and ketamine for treatment-resistant depression. The center's Feinstein Family Human Neuropsychopharmacology Laboratory is one of only a handful of US facilities licensed to dispense federal Schedule I substances for research.

Northwestern University's Feinberg School of Medicine Department of Psychiatry & Behavioral Sciences conducts ketamine research including trials for TBI-associated symptoms and perioperative depression, and has begun preclinical psilocybin studies examining psychedelic and psychotomimetic mechanisms. The department also offers clinical trials in schizophrenia, bipolar disorder, depression, and anxiety, with the Osher Center for Integrative Health incorporating psychedelic-assisted therapy education.

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that has advanced MIJ821 — a selective GluN2B/NR2B NMDA receptor antagonist — through a Phase 2 proof-of-concept trial for treatment-resistant depression, exploring the same ketamine-like NMDA antagonism pathway. MIJ821's rapid-acting antidepressant mechanism is part of Novartis's broader CNS drug discovery pipeline.

Global full-service biotech-focused CRO supporting development across clinical phases, with publicly stated psychedelic trial collaborations and formal partnerships with experienced psychedelics research centers.

Numinus Wellness Inc. is a Vancouver-based mental health company focused on psychedelic-assisted therapy: it provides practitioner training, clinical research services, and (formerly) operated clinics and a Health Canada‑licensed bioscience laboratory for psychedelic research and product development.

Octarine Bio is a Danish synthetic biology company producing psilocybin and other neuroactive compounds via proprietary yeast fermentation. Founded in Copenhagen, the company raised $11M from 13 investors including DSM-Firmenich and has partnered with Clerkenwell Health to supply GMP psilocybin for clinical trials. Octarine Bio's platform is based on engineering yeast to express the biosynthetic pathway for psilocybin and related alkaloids.

Ontario Shores Centre for Mental Health Sciences is a specialized mental health facility in Whitby, Ontario affiliated with the University of Toronto Department of Psychiatry, offering investigational ketamine infusion therapy for treatment-resistant depression. The centre has conducted trials comparing ketamine to ECT and combining IV ketamine with internet-based CBT (Ket-CBT) for suicidality in TRD, and holds the world's first Level 7 EMR maturity validation for a mental health facility.

Canadian GMP-certified manufacturer of pharmaceutical-grade psilocybin and MDMA, licensed by Health Canada. Optimi's facility in Princeton, British Columbia is one of the largest legal psilocybin production operations in North America. Supplies clinical trial material to researchers in Australia, Israel, and Canada.

Researchers at the Social Neuroscience and Psychotherapy (SNAP) Lab at OHSU are investigating the therapeutic potential of psychedelics. Assistant Professor of Psychiatry, Dr Chris Stauffer, is the current director of the lab. SNAP Lab aims to maximize the benefits of therapeutic alliance and psychotherapy through the adjunct use of social psychopharmacology, such as oxytocin, MDMA, and psilocybin. Dr Stauffer led a research team from OHSU in a clinical trial exploring the effects of psilocybin in methamphetamine use disorder. With Oregon becoming the first state to legalize psilocybin-assisted therapy, more research is taking place at OHSU.

Oregon Research Institute's Center for Evaluation Services (ORI CES) is a 501(c)(3) non-profit research unit based in Eugene, Oregon that provided methodological and evaluation support to the SAMATI (Social Anxiety MDMA-Assisted Therapy Investigation) trial — an investigator-initiated study by Portland Psychotherapy exploring MDMA-assisted therapy for generalized social anxiety disorder, with study drug supplied by MAPS PBC.

Orygen is an Australian youth mental health organisation and research centre focused on prevention, early intervention, clinical care, and translational research for young people with mental ill-health.

Otsuka Pharmaceutical Co., Ltd. is a Japanese multinational pharmaceutical company (parent: Otsuka Holdings, TYO: 4578) with a core focus on neuropsychiatry, oncology, and cardiovascular/renal medicine. It entered the psychedelic medicine space by acquiring Canadian biotech Mindset Pharma for ~CAD $80M (~USD $59M) in September 2023, giving it exclusive rights to MSP-1014 and a broader pipeline of novel 5-HT2A agonists. The deal was seeded by an earlier $5M joint development agreement between Mindset and the McQuade Center for Strategic Research and Development (an Otsuka R&D vehicle). MSP-1014 is a Phase 2 psilocin prodrug for MDD, with trials underway in the UK.

The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and affiliated with the University of Ottawa, conducting clinical and translational research spanning 16 departments and over 1,700 scientists and trainees. OHRI has contributed to psilocybin research for psychological and existential distress in palliative care, part of Canada's expanding academic psychedelic medicine research.

The P3A project is a multidisciplinary research initiative in Quebec exploring the acceptability and accessibility of psilocybin-assisted therapy for palliative and end-of-life care, focusing on alleviating existential distress.

PPD Development (now part of Thermo Fisher Scientific's clinical research business) is one of the world's largest contract research organizations (CROs), providing trial management and bioanalytical services for clinical programs including DoD-sponsored studies on SLS-002 (intranasal racemic ketamine) for PTSD in military personnel and veterans through the M-PACT adaptive platform trial.

The PSIPET study at Karolinska Institute is the first Phase II randomized clinical trial in Sweden investigating psilocybin for depression. The research utilizes PET and MRI imaging to examine synaptic density and the biological mechanisms underlying psilocybin's therapeutic effects.

The Palner Lab at SDU utilizes preclinical in vivo imaging and pharmacology to understand neuronal circuits involved in anxiety and OCD. Led by Mikael Palner, the lab investigates how classic psychedelics influence neuronal plasticity and stress resilience.

Parc de Salut Mar is a public hospital consortium in Barcelona, Spain, whose research arm IMIM (Hospital del Mar Medical Research Institute) has conducted controlled human pharmacology studies of MDMA and novel psychoactive substances. Their Integrative Pharmacology and Systems Neuroscience Research Group ran landmark double-blind crossover trials comparing mephedrone to MDMA in healthy volunteers and investigating MDMA pharmacokinetics by sex and CYP2D6 genotype.

Patient network platform with treatment and condition self-reporting, including explicit psilocybin treatment pages and community-reported outcomes context.

Leading academic hospital in Beijing affiliated with Peking University. Has conducted ketamine clinical trials including a randomized study of low-dose ketamine for perinatal depression, contributing to China's growing body of research on rapid-acting antidepressant therapies.

Perception Neuroscience is a New York–based biopharmaceutical subsidiary of atai Life Sciences developing PCN-101 (arketamine, R-ketamine) as a potentially safer, lower-dissociation alternative to racemic ketamine for treatment-resistant depression. The company completed a Phase 1 single-ascending-dose study in 58 healthy volunteers and a Phase 2a double-blind, placebo-controlled trial in TRD patients, with a collaboration with Otsuka Pharmaceutical for the Japanese market.

The Peter Boris Centre for Addictions Research (PBCAR) is a joint addiction research centre of McMaster University and St. Joseph's Healthcare Hamilton in Canada, directed by Dr. James MacKillop. PBCAR is conducting a Phase 2 clinical trial of psilocybin-assisted psychotherapy — two 25 mg psilocybin sessions combined with an 8-week Motivational Enhancement Therapy program — for cannabis use disorder.

Pfizer is a multinational pharmaceutical corporation that, through Pfizer Canada and the Canadian Pain Society, co-funded the KetHead multi-center Phase 3 RCT (NCT05306899) evaluating high-dose IV ketamine for chronic daily headaches at Toronto Western Hospital and Sinai Health System. The trial targets NMDA receptor-mediated central sensitization underlying refractory headache disorders.

PharmAla Biotech (CSE: MDMA) is a Canadian biotech specialising in MDXX-class molecule R&D and GMP MDMA manufacturing. Founded in January 2021 by CEO Nick Kadysh, the company operates two business lines: (1) LaNeo — clinical-grade GMP MDMA supplied to research institutions worldwide under a supply-for-data model, now with a US distribution hub and agreements spanning Mt. Sinai, Yale, UAB, University of Washington, and institutions in Norway and Netherlands; and (2) proprietary drug development led by ALA-002, a patented non-racemic MDMA (70–80% R-MDMA / 20–30% S-MDMA) targeting social anxiety in autism, plus APA-001, a novel non-scheduled MDXX molecule discovered via University of Windsor AI collaboration. ALA-002 holds US Patent No. 12,053,452 (composition of matter, issued 2024), MHRA written guidance that no further preclinical data is needed, and FDA NCE classification. Phase 2a clinical trial drug substance manufacture was contracted with a UK CDMO in December 2025 in preparation for an Australian Phase 2a with University of Sydney (Dr. Adam Guastella). Revenue grew 95% in FY2024 to C$1.04M from MDMA product sales. Note: master list originally classified as private, but is publicly listed on CSE.

PharmaDrug is a Canadian specialty pharmaceutical company focused on the research and development of controlled substances and natural medicines. Through its Sairiyo Therapeutics subsidiary, the company is developing a DMT candidate with FDA Orphan Drug Designation for prevention of ischemia-reperfusion injury in organ transplants, and is also studying DMT for ophthalmic indications. PharmaDrug also distributes medical cannabis in the EU via PharmaDrug Production GmbH.

Canadian specialty pharmaceutical company focused on ketamine-based therapies for psychiatric and neurological conditions. KETARX™ (racemic ketamine IV) received FDA approval in August 2025, making PharmaTher one of the first Canadian companies to achieve US regulatory approval for a ketamine product. Also developing KETABET, a proprietary combination of ketamine and betaine.

The Pharmaceutical Research Unit (PRU) is the first contract research organization established in Jordan (1993), headquartered in Amman and accredited by the US FDA, EU authorities, and multiple MENA health agencies. PRU served as the clinical site and collaborating organization for Lobe Sciences' Phase 1 first-in-man pharmacokinetic study of psilocin mucate (L-130), a stabilized psilocin salt with near-100% bioavailability investigated as a low-dose at-home therapeutic.

Pompeu Fabra University (UPF) is a public research university located in Barcelona, Spain, founded in 1990 and named after Catalan philologist Pompeu Fabra. It is known for strong research performance and international rankings across social sciences, law, economics and related fields.

Pontificia Universidad Catholica de Chile (UC Chile) is one of Chile's most prestigious research universities, whose Division of Anesthesiology in Santiago has conducted ketamine pharmacokinetic/pharmacodynamic research including the Keta-ANI study, which characterized the temporal antinociceptive profile of IV ketamine bolus using the Analgesia Nociception Index and developed an effect-site TCI model for analgesic dosing.

The Portland Institute for Psychedelic Science (PIPS) is a US-based research-oriented institute supporting psychedelic science initiatives, program development, and practice-adjacent translational work.

Portland Psychotherapy is a Portland, Oregon clinic, research, and training center that integrates psychedelic science into evidence-based clinical practice, conducting clinical trials of MDMA-assisted therapy for social anxiety disorder and offering psychedelic integration services. Their distinctive model funds peer-reviewed research through clinical revenue, resulting in exceptionally well-trained therapists in psychedelic-assisted care.

The Portland VA Research Foundation, Inc. is a non-profit entity supporting clinical research at the Portland VA Health Care System in Oregon. It sponsors the SNaP Lab's psilocybin-enhanced psychotherapy trial for methamphetamine use disorder (with the Cohen Foundation) and the Group-MVP MDMA group therapy trial for Veterans with PTSD, both led by Dr. Christopher Stauffer, an OHSU Associate Professor of Psychiatry.

The Section of Psychiatry at the University of the West Indies (UWI) Mona, led by Professor Roger Gibson within the Faculty of Medical Sciences' Department of Community Health and Psychiatry, is conducting a clinical trial assessing the efficacy of microdosed psilocybin on reducing anxiety and depression levels in adults in Jamaica.

Providence Care Hospital in Kingston, Ontario hosts Canada's first hospital-based psychedelic research centre — the Centre for Psychedelics Health and Research (opened 2024) — in partnership with Queen's University and CAN-BIND, conducting psilocybin and LSD research alongside its established IV ketamine clinic for treatment-resistant depression led by Dr. Claudio Soares.

Psilera is a Florida-based drug discovery company developing non-hallucinogenic psilocybin derivatives and outpatient-compatible psychedelic medicines. Founded in 2019, the female co-founded company has a proprietary compound library of over 1 million novel compounds. Lead candidate PSIL-006 is a non-hallucinogenic psilocybin derivative targeting behavioral variant frontotemporal dementia (bvFTD), with positive preclinical in vivo efficacy data in humanized tau mouse models. Earlier compounds PSIL-001/002 (DMT derivatives) showed improvements in learning and memory.

Psilo Scientific Ltd is a Health Canada-licensed psilocybin producer and wholly-owned subsidiary of Filament Health Corp (NEO: FH), supplying purified botanical psilocybin (PEX010) to clinical trials including the PSYCHED-PAL palliative care microdosing study; it also licensed PEX010 to Cybin for Phase 2 trials in treatment-resistant depression and alcohol use disorder.

Psy Therapeutics is a Cambridge, MA-based drug discovery company developing novel small-molecule NCEs for neuropsychiatric and neurological disorders. Founded around 2019 by MGH psychiatrists Jerry Rosenbaum, Roy Perlis, and Maurizio Fava with Brant Binder, the company applies DNA-encoded library screening (via X-Chem) and validated CNS targets. Pipeline includes PSY-05 (anxiety), PSY-06 (MDD), PSY-02 (dementia/tau aggregation), and programs in Parkinson's and chronic pain. Non-hallucinogenic, psychedelic-inspired CNS approach.

Not-for-profit psychedelic clinical research consortium offering shared site infrastructure, harmonized SOPs, benchmarking, centralized recruitment support, and patient registry workflows.

Psychedelic production company focused on naturally derived psilocybin ingredients and export-linked API development for research and clinical pathways.

European collaborative research project focused on psychedelic-assisted therapy in palliative care contexts.

The Psychedelic Data Society is a US-based citizen-science nonprofit managing the Psychedelic Data Project, a global harm reduction and research initiative that collects participant-contributed data to accelerate psychedelic science and inform evidence-based drug policy reform.

HaEmek Medical Center's Psychedelic Research and Treatment Center is a pioneer in MDMA-assisted therapy (MDMA-AT) for combat-related PTSD. It is notable for offering group therapy models and utilizes advanced neuroimaging tools (EEG/fMRI) to monitor clinical outcomes and brain mechanisms.

PRISM is an Australian nonprofit organization advancing evidence-based psychedelic science, policy, and public education through research communication, expert engagement, and policy-facing advocacy.

The Psychedelic Resource Group at Trinity College Dublin advances translational psychedelic research across psychiatry and neuroscience, with a focus on clinical applications, public-health integration, and evidence generation for psychedelic-assisted care.

The Psychedelic Substances Research Group at Charité investigates various aspects of psychedelics, including their therapeutic applications, sociocultural implications, and harm reduction strategies. They lead the PsychedELSI project, focusing on ethical, legal, and social aspects of psychedelic research.

The Psychedelics and Contemplation Lab at McGill University investigates non-ordinary states of consciousness, spiritual practices, and novel clinical interventions. Co-directed by Dr. Kyle Greenway and Dr. Michael Lifshitz, the lab takes a relational and interpersonal approach, examining how extra-pharmacological factors such as set, setting, and therapeutic relationships shape psychedelic experiences and outcomes. The lab is part of a broader psychedelic research ecosystem at McGill that includes the Neurobiological Psychiatry Unit led by Dr. Gabriella Gobbi, which conducts preclinical and animal model studies on LSD, psilocybin, DMT, and 5-MeO-DMT to uncover their mechanisms of action at the neuronal and circuit level, as well as computational neuroscience work at The Neuro mapping psychedelic experiences to neurotransmitter systems using large-scale data analysis.

The Psychiatric University Hospital Zurich (PUK) is affiliated with the University of Zurich and home to Franz Vollenweider's pioneering psychedelic neuroscience group, active since the 1990s; research includes PET imaging with psilocybin, S- and R-ketamine, MDMA, and DMT+harmine formulations, including a completed 2023 RCT of psilocybin (0.215 mg/kg) vs. placebo for major depressive disorder.

Psyence Australia Pty Ltd is the Australian subsidiary of Psyence Biomed Ltd (Nasdaq: PBM), a company focused on nature-derived botanical psilocybin medicine; it received HREC approval to conduct a Phase IIb randomized double-blind trial evaluating natural psilocybin (NPX-5 at 10 mg and 25 mg) versus an active low-dose comparator for adjustment disorder in palliative care cancer patients, with sites in Melbourne and Perth.

Psyence Biomedical (Nasdaq: PBM) is a clinical-stage company developing nature-derived (non-synthetic) psilocybin and ibogaine therapeutics. Spun out of Psyence Group via SPAC in early 2024, PBM is conducting a Phase IIb trial of its NPX5 botanical psilocybin product for Adjustment Disorder in cancer patients receiving palliative care — with three active sites across Australia (Perth and Melbourne). The company positions itself as the first Nasdaq-listed company focused on nature-derived psychedelic therapeutics and claims a first-mover position in psilocybin for Adjustment Disorder. It also holds worldwide exclusive licensing rights for nature-derived psilocybin in AUD and has secured GMP-compliant ibogaine HCl supply for a planned SUD programme. Note: the original CSE-listed parent (PSYG) entered an amalgamation agreement with a Ghanaian mining company in November 2025 (trading halted); the psychedelic R&D resides entirely in the separately-listed Nasdaq entity (PBM).

Psygen is a Canadian GMP-certified active pharmaceutical ingredient (API) manufacturer specialising in psychedelic compounds for clinical research. Founded in 2019 and based in Calgary, Alberta, the company produces pharmaceutical-grade psilocybin, LSD, MDMA, DMT, ibogaine, and 5-MeO-DMT under DEA- and Health Canada-compliant conditions, supplying clinical trial sponsors and research institutions. Psygen raised $5.5M to expand its GMP manufacturing capabilities.

Psyrin Inc. is a UK-based AI health startup founded by researchers from King's College London that develops speech analysis algorithms using machine learning to rapidly assess serious mental illness from brief voice recordings; its patent-pending technology achieved 86% accuracy distinguishing psychosis-spectrum disorders from other conditions in a Translational Psychiatry publication, and is being studied as a tool for predicting treatment response to psychiatric interventions.

Purdue University is a public research university in West Lafayette, Indiana, United States. It is the flagship campus of the Purdue University system and is well known for strong programs in engineering, agriculture, and technology.

US-based API CDMO with stated capabilities for Schedule I psychedelic compounds, supporting clinical trial supply and cGMP manufacturing workflows.

Qinghai Red Cross Hospital (青海红十字医院) is a JCI-accredited 3A-grade comprehensive hospital with 2,000 beds in Xining, Qinghai Province, China, established in 1949 and the first hospital in western China to receive JCI accreditation; affiliated researchers are participating in clinical trials investigating intraoperative esketamine as a preventive treatment for postpartum depression following cesarean section.

Qinghai University (青海大学) is a public comprehensive research university in Xining, Qinghai Province, China; its affiliated hospital and medical faculty are involved in clinical research investigating intraoperative esketamine as a preventive treatment for postpartum depression in women undergoing cesarean section.

Digital research platform running psychedelic self-report and behavioral studies through app-based participation, including Microdose.me cohorts.

Quantified Citizen Technologies Inc. is a Canadian privacy-centric mobile health research platform powering decentralized citizen-science studies; it built the world's first mobile app for psychedelic microdosing data collection (Microdose.me) with over 19,000 participants worldwide, whose findings were published in Nature Scientific Reports, and continues to host multiple psychedelic observational studies in partnership with MAPS, UBC, and researchers including Paul Stamets and James Fadiman.

The Centre for Psychedelics Health and Research, a joint project with Providence Care, aims to address fundamental questions regarding psychedelics in healthcare and expand clinical understanding of psychedelic-assisted therapies.

RIVER Foundation is a US-based nonprofit conducting observational research on ketamine treatment plans for chronic conditions, including an ongoing study led by a doctoral candidate in clinical psychology; through its Assimilation Program, it connects patients with licensed physicians who can prescribe home-based ketamine sessions with integration support.

Radboud University Medical Center (Radboudumc) is one of the Netherlands' leading academic medical centers, located in Nijmegen. It combines patient care, education, and scientific research under one roof, with a particular strength in neuroscience through its Donders Centre for Medical Neuroscience. Radboudumc is known for its translational research approach. The medical centre bridges fundamental science and clinical practice across areas including oncology, rare diseases, and psychiatry. In the field of psychedelic medicine, Radboudumc has been involved in ibogaine research, conducting studies through its Department of Pharmacology–Toxicology and Department of Psychiatry, examining ibogaine as a potential treatment for opioid use disorder. This work included a clinical study evaluating the cardiac, cerebellar, and psychomimetic safety of ibogaine in opioid-dependent patients, contributing important safety data to the broader scientific understanding of this compound.

Rady Children's Hospital San Diego is a leading US pediatric academic medical center with over 200 active clinical trials; its emergency department research team is studying whether a single low-dose IV ketamine infusion reduces depression symptoms and suicidal ideation in adolescents compared to placebo, aiming to expand rapid treatment options in the emergency setting.

Reconnect Labs AG is a Swiss clinical-stage company and University of Zurich spin-off developing precision psychopharmacology therapeutics, including sublingual DMT/harmine, sublingual 5-MeO-DMT, and sublingual dexmedetomidine. Founded in 2021 by Dr. Davor Kosanic (CEO) and co-founders from the Psychiatric University Clinic Zurich and ETH Zurich, building on ~30 years of in-human psychedelic research. The company raised CHF 22M+ (CHF 12M equity across Seed 2021 and Series A 2023–2025; CHF 10M in competitive grants from investors including Esperante Ventures, Lionheart Ventures, Negev Capital, and Noetic Fund) before emerging from stealth in August 2025. Their microcarrier-based transmucosal delivery platform (exclusively licensed) dramatically reduces inter-subject PK variability for DMT/harmine vs. oral ayahuasca and eliminates vomiting. RE03 (sublingual dexmedetomidine for insomnia in PTSD) is the most advanced programme with Swissmedic approval and FDA accelerated pathway confirmed.

Canadian company producing and distributing legal psilocybin magic truffles to adult consumers in the Netherlands under the iMicrodose and Trip brands. Also developing pharmaceutical-grade psilocybin formulations through its Irvine Pharma subsidiary for clinical and research applications.

Region Orebro County is a Swedish regional public health authority in central Sweden whose University Hospital (Universitetssjukhuset Orebro) is a participating site in the CAPSI trial, a randomized study investigating single-dose psilocybin-assisted psychotherapy for major depression in adult cancer patients.

Remedi Therapeutics is a private biotech company developing a novel oral DMT formulation combined with a best-in-class, ultra-selective monoamine oxidase A inhibitor (RIMA) to create a predictable, convenient ayahuasca-like therapeutic. Unlike traditional ayahuasca, which uses plant-sourced harmine with off-target effects, Remedi's proprietary RIMA avoids gastrointestinal distress, tremors, and hypertensive risk, enabling pharmaceutical-grade oral DMT delivery for neuropsychiatric conditions.

Remedy is a Toronto-based mental health innovation community founded by Dr. Anne Wagner, C.Psych., that conducts psychedelic research through its Remedy Institute arm; Dr. Wagner leads two MDMA-assisted psychotherapy trials for PTSD — a pilot open-label study combining MDMA with Cognitive Processing Therapy (CPT), and a randomized controlled trial combining MDMA with Cognitive Behavioral Conjoint Therapy (CBCT), a couples therapy approach.

Reset Pharma is a US clinical-stage biotechnology company developing psilocybin-based treatments for patients with life-altering diseases. Its lead candidate RSTP1000 (oral psilocybin) targets demoralization syndrome in cancer patients — a condition with no approved treatments. In November 2023 the company received FDA IND clearance to initiate a Phase 2b multicenter, randomized, dose-ranging trial. The company holds an exclusive worldwide licence from NYU Langone Health and licenses drug supply from Filament Health Corp. Reset has raised $11.1M led by Merida Capital Partners.

Resilient Pharmaceuticals (formerly Lykos Therapeutics, formerly MAPS PBC) is a US-based public benefit corporation developing MDMA-assisted therapy for PTSD. It was founded in 2014 by MAPS (Multidisciplinary Association for Psychedelic Studies) as a commercial spinout to carry MAPS’ three decades of MDMA research through late-stage trials and regulatory approval. After completing two Phase 3 trials and filing an NDA in 2024, the FDA issued a Complete Response Letter (CRL) in August 2024, citing concerns about functional unblinding, durability of response, safety reporting at two trial sites, and the challenge of blinding psychedelic studies. The CRL requested a third Phase 3 trial. Following the rejection, the company laid off approximately 75% of staff. In May 2025, billionaire investors Antonio Gracias (Gracias Foundation) and Sir Christopher Hohn (TCI Fund) led a $50 million Series B recapitalisation, installing new leadership: CEO Mike Burke and CMO Javier Muniz. Rick Doblin, MAPS’ founder, remains supportive of the new direction. The company rebranded from Lykos Therapeutics to Resilient Pharmaceuticals on 28 August 2025, and continues to negotiate a path to FDA approval for MDMA-assisted therapy for PTSD.

Canadian biotech (formerly Nova Mentis Life Science, renamed November 2024) developing psilocybin therapy for Fragile X Syndrome and autism spectrum disorder. Lead candidate NM-1001 received Health Canada authorisation for a Phase IIA clinical trial, making it one of the few psilocybin programmes targeting neurodevelopmental conditions.

The Rett Syndrome Research Trust (RSRT) is a US-based nonprofit dedicated to curing Rett syndrome (RTT) that funded, held the IND for, and oversaw a randomized double-blind placebo-controlled crossover trial of oral ketamine in girls aged 6-12 with RTT; the study confirmed safety and tolerability and demonstrated EEG evidence of NMDA receptor target engagement, supporting further trials with longer duration or higher doses.

Reunion Neuroscience is a private, Toronto-based clinical-stage biopharmaceutical company focused on short-duration, serotonergic psychedelic therapies for postpartum depression, adjustment disorder, and anxiety. Spun out of Field Trip Health in 2022, the company raised a $103M Series A in May 2024 (co-led by Novo Holdings and MPM BioImpact) and went private under CEO Greg Mayes. Its lead asset RE104 (luvesilocin) — a subcutaneous prodrug of 4-OH-DiPT, a psilocybin-like 5-HT2A agonist with shorter duration than psilocybin — met the primary endpoint of its RECONNECT Phase 2 trial for PPD (Aug 2025) and received FDA Breakthrough Therapy Designation on February 23, 2026. A single pivotal Phase 3 trial is planned for 2026.

Canadian biotech developing psilocybin formulations for substance use disorders and neurological conditions. Lead programme is an oral psilocybin thin-film strip in a Phase I/II clinical trial for methamphetamine use disorder, with approximately 50% enrolment completed. Also conducting preclinical research on psilocybin for stroke recovery and inflammation.

Copenhagen University Hospital Rigshospitalet is Denmark's foremost academic medical center, home to the Neurobiology Research Unit (NRU) led by Professor Gitte Moos Knudsen, which has conducted psychedelic neuroimaging research with psilocybin and LSD since 2017; its affiliated NOESIS clinical research unit runs active trials investigating psilocybin for depression, OCD, and cancer-related distress, plus LSD serotonin 2A receptor occupancy imaging studies, in collaboration with Imperial College London and Karolinska Institutet.

US poison center and toxicology surveillance organization supporting data collection and safety monitoring operations.

Rose Hill Life Sciences is a North American psychedelic life sciences company that supplies research-grade Psilocybe cubensis biomass and sponsors clinical trials, including the PHATHOM study testing psilocybin combined with physical therapy to restore motor function in stroke patients; it also collaborates with Johns Hopkins, the University of Guelph, and the Canadian Centre for Psychedelic Science, and has operated a psilocybin mushroom cultivation facility since 2015.

Roswell Park Comprehensive Cancer Center in Buffalo, NY operates a Psychedelic Science Initiative (PSI) conducting research on psilocybin and ketamine for cancer patients; active trials include an open-label psilocybin microdosing study for chronic cancer pain and opioid reduction, a Phase 2 trial of the novel psychedelic RE104 for adjustment disorder in cancer patients, and a palliative esketamine clinic for co-morbid treatment-resistant depression.

Royal North Shore Hospital (RNSH) in St Leonards, New South Wales, Australia is a major academic medical center within the Northern Sydney Local Health District; its CADE Clinic (Department of Psychiatry) and Northern Sydney Anaesthetic Research Institute have participated in multiple ketamine trials including the KADS Phase 3 RCT of subcutaneous racemic ketamine for treatment-resistant depression, and real-world esketamine studies for depression management.

The Royal University Hospital Foundation is the charitable fundraising arm of Royal University Hospital in Saskatoon, Saskatchewan, which has invested over $194 million into research, education, and patient care at Saskatchewan's largest academic hospital; the Foundation has supported psychiatry research including ECT and ketamine anesthesia comparative trials and Dr. Evyn Peters' groundbreaking work using intranasal racemic ketamine for hospitalized patients with treatment-resistant depression.

The Quebec Network on Suicide, Mood Disorders and Associated Disorders (RQSHA) is a publicly-funded interdisciplinary research network supported by the Fonds de recherche du Québec that brings together researchers from across Quebec to study suicide, mood disorders, and substance use; it has funded several ketamine trials including the 'Montreal Model' study integrating psychedelic-informed ketamine therapy with psychological support for severe treatment-resistant depression, and research on music as an intervention to improve ketamine tolerability in depression treatment.

SUNY New Paltz (State University of New York at New Paltz) is a public university in New Paltz, New York, that is part of the SUNY system. It offers undergraduate and graduate programs across the arts, sciences, education, and professional fields.

Salem Anaesthesia Pain Clinic is an outpatient anesthesia and pain management clinic in Surrey, British Columbia, led by Dr. Olu Bamgbade, a clinical assistant professor with over 25 years of experience in the UK, USA, and Canada; the clinic offers IV ketamine infusion for treatment-resistant depression, mood disorders, and chronic pain, and has conducted clinical research demonstrating that ketamine enhances both analgesia and mood outcomes in chronic pain patients.

The San Francisco Department of Public Health is the public health agency of the City and County of San Francisco, operating clinics, HIV/AIDS programs, and behavioral health services for over 125,000 patients annually; through its Behavioral Health Services division, it is conducting the KARE (Ketamine-Assisted Recovery) trial investigating ketamine-assisted psychotherapy for methamphetamine use disorder in publicly-insured adults with or at risk for HIV, integrating harm reduction principles with neuroplasticity-based addiction treatment.

The Saskatoon Health Region (now integrated into the Saskatchewan Health Authority) was the regional health authority responsible for hospital and community health services in Saskatoon and surrounding areas in Saskatchewan, Canada; through Royal University Hospital, it supported pioneering ketamine research for psychiatric conditions including comparative ECT and ketamine anesthesia trials, and the intranasal racemic ketamine protocol for hospitalized patients with treatment-resistant depression developed by Dr. Evyn Peters.

Scottsdale Research Institute (SRI) is an Arizona-based research organization conducting the world's first controlled clinical trial of whole psilocybin mushrooms. Their FDA-approved Phase 1 study tests naturally-grown whole mushrooms (30mg psilocybin dose) for PTSD in first responders and military veterans, funded by $5M from the Arizona Legislature. The study explores the entourage effect hypothesis compared to isolated synthetic psilocybin. Led by Dr. Sue Sisley.

Seaport Therapeutics is a Boston-based biopharmaceutical company developing neuropsychiatric medicines using its proprietary Glyph™ lymphatic delivery platform. The Glyph technology bypasses first-pass hepatic metabolism by routing drugs through the lymphatic system, improving oral bioavailability. Its lead candidate SPT-348 (Glyph2BLSD™) is a prodrug of BOL-148 (2-bromo-LSD), a non-hallucinogenic neuroplastogen targeting headache disorders and TRD. The company raised $325M across a $100M Series A (2024) and $225M Series B (2024–2025), backed by PureTech Health, ARCH Venture Partners, Third Rock Ventures, and General Atlantic.

US clinical-stage biopharmaceutical company developing intranasal racemic ketamine (SLS-002) for major depressive disorder with acute suicidal ideation and PTSD. Completed Phase 2 trials before filing for Chapter 11 bankruptcy in November 2024 and being delisted from Nasdaq; trading continues on OTCQB.

Shalvata Mental Health Center is a 114-bed comprehensive psychiatric hospital founded in 1956 in Hod HaSharon, Israel, affiliated with Clalit Health Services and the Sackler Faculty of Medicine at Tel Aviv University; it is one of Israel's most active psychedelic research sites, having conducted trials comparing intranasal versus intravenous ketamine administration, MDMA-assisted psychotherapy for borderline personality disorder, and ketamine combined with cognitive behavioral analysis system of psychotherapy (CBASP) for chronic treatment-resistant depression.

Israel's largest hospital and a major academic medical center affiliated with Tel Aviv University. A key site for MDMA-assisted psychotherapy trials through MAPS Israel and other research programs, as well as ketamine studies for treatment-resistant depression.

Shenox Pharmaceuticals LLC is a US-based specialty pharmaceutical company developing innovative transdermal delivery systems for psychiatric medications; their lead program SHX-001 is a ketamine transdermal patch that delivers sustained, controlled ketamine plasma concentrations for up to 7 days to treat major depressive disorder while minimizing the adverse effects, abuse potential, and clinic-visit burden of IV and intranasal ketamine, with FDA IND approval granted in 2018 and an ongoing Phase 1 pharmacokinetics and antidepressant efficacy trial.

Sheppard Pratt Health System is a leading non-profit psychiatric hospital and health system in Towson, Maryland, home to the Center of Excellence for Psilocybin Research and Treatment — the first international center of its kind — established in partnership with COMPASS Pathways; it has conducted landmark psilocybin trials including the first trial for bipolar type II depression (published in JAMA Psychiatry with 80% remission at 12 weeks), psilocybin for treatment-resistant depression (published in NEJM), and psilocybin for TRD with chronic suicidal ideation.

Shortwave Life Sciences is a UK-listed biopharmaceutical company developing a proprietary psilocybin and beta-carboline buccal film formulation for the treatment of anorexia nervosa. The mucoadhesive film delivery system enables improved bioavailability and rapid onset by bypassing first-pass metabolism, and the company has secured an investigator-initiated Phase 2 clinical trial agreement with Sheba Medical Center in Israel — targeting a condition with no FDA-approved pharmacological treatment.

Global eClinical and endpoint-science provider offering psychedelic-focused trial methodology, protocol-to-endpoint support, and purpose-built data quality workflows for psychiatry and CNS programs.

US-listed clinical-stage biotech developing psychedelic and ketamine-based therapies for PTSD and chronic pain. SPC-15 is an intranasal 5-HT4 serotonin receptor agonist for PTSD in IND-enabling GLP studies. SP-26 is a proprietary ketamine implant for fibromyalgia being co-developed with the University of Maryland.

Singapore Health Sciences Authority adverse-event reporting framework for therapeutic products and clinical trials. Included as core safety-monitoring infrastructure; no dedicated psychedelic public reporting surface identified.

Small Pharma Ltd was a UK-based psychedelic biotechnology company that conducted the world's first clinical trials of DMT-assisted therapy for major depressive disorder; their lead compound SPL026 (N,N-dimethyltryptamine fumarate) delivered a short-lived ~20-minute psychedelic experience via IV or IM administration, and the Phase I/IIa program in collaboration with Imperial College London's Centre for Psychedelic Research demonstrated consistent quality of psychedelic response and antidepressant effects; the company was subsequently acquired by Cybin Inc. to create the industry's largest deuterated DMT program.

Solvonis Therapeutics plc (LSE: SVNS) is a London-listed, clinical-stage biopharmaceutical company developing evidence-based treatments for addiction and mental health disorders. Formed through the rebranding of Graft Polymer (UK) PLC and the acquisition of Awakn Life Sciences Corp (NEO: AWKN, completed May 2025), Solvonis inherited Awakn's lead programme SVN-001 — IV ketamine combined with manualised CBT — now in Phase 3 for severe alcohol use disorder, co-funded by the UK NIHR. The company also advances SVN-002 (buccal/sublingual esketamine for US AUD) and SVN-SDN-14 (novel SDN receptor modulators for PTSD at preclinical stage), plus an AI-driven CNS discovery engine.

Soneira is a private psychedelic biotech company developing synthetic ibogaine therapies for neuropsychiatric conditions, with a primary focus on traumatic brain injury (TBI). The company has raised $15 million from Sergey Brin's Catalyst4 investment vehicle and is working to advance the first FDA-approvable synthetic ibogaine candidate to clinical trials.

Led by Dr. Soravia at the University Clinics UPD, this group focuses on developing psychobiological approaches that integrate effective psychotherapy methods with the administration of psychedelic substances to treat mental disorders, particularly substance use disorders, stress- and trauma-related conditions, and anxiety.

Soroka Medical Center, in collaboration with Ben-Gurion University, has a strong background in medical cannabis research for PTSD and ASD. Their faculty also collaborate on broader psychedelic studies investigating MDMA for trauma prevention.

Soterix Medical is a US-based medical device company specializing in non-invasive neuromodulation technology, primarily transcranial direct current stimulation (tDCS); the company develops tDCS devices used in clinical research trials for treatment-resistant depression, bipolar depression, and substance use disorders, and has contributed to ketamine biomarker validation research exploring how neuromodulation biomarkers can predict or complement ketamine treatment response in patients with major depressive disorder.

South London and Maudsley NHS Foundation Trust (SLaM) is the UK's leading academic mental health Trust, home to Maudsley Hospital and the NIHR Maudsley Biomedical Research Centre; in partnership with COMPASS Pathways and King's College London's Institute of Psychiatry, it has established a dedicated Psychedelics and Mental Health Research Centre conducting psilocybin Phase 3 trials for treatment-resistant depression, MDMA therapy for PTSD, 5-MeO-DMT studies, and the SIGNATURE synaptic imaging biomarker trial, aiming to treat 650–700 patients over five years.

South West Sydney Local Health District (SWSLHD) is a large public health network serving south-west Sydney, New South Wales, Australia; it has participated in cutting-edge psychedelic research trials including KET-DUAL, a pilot study of ketamine-enhanced therapy for patients with co-occurring alcohol use disorder and depression, and MPATHY, an RCT of MDMA-assisted prolonged exposure therapy for comorbid alcohol use disorder and post-traumatic stress disorder.

Southern Methodist University (SMU) is a private research university in Dallas, Texas, offering the course "Plants of the Gods: Religion and Psychedelics" through its Religious Studies department, taught by University Distinguished Teaching Professor Dr. G. William Barnard. The course examines the historical and cultural significance of entheogenic plants — including peyote, ayahuasca, and psilocybin mushrooms — across diverse religious traditions.

Australian full-service CRO focused on early-phase clinical development in APAC, with confirmed role supporting a Phase IIb psilocybin-assisted psychotherapy trial and broad operational trial services.

Southwest University is a public comprehensive university in Chongqing, China, with strengths across life sciences, psychology, and interdisciplinary research.

Southwestern College is a public community college in Chula Vista, California, part of the Southwestern Community College District. It offers associate degrees, transfer pathways, workforce training, and continuing education across multiple campuses.

Spaulding Rehabilitation Hospital is a leading rehabilitation hospital in Boston, Massachusetts, affiliated with the Mass General Brigham health system and home to the Scott Schoen and Nancy Adams Discovery Center for Chronic Pain Recovery. It is pioneering psychedelic research in pain medicine through the first clinical trial of MDMA-assisted therapy for fibromyalgia, which uses hyperscan neuroimaging to investigate how MDMA influences brain-to-brain dynamics between patient and therapist to produce analgesia, in collaboration with PharmAla Biotech.

The Special Operations Care Fund (SOC-F) is a US non-profit organization based in Atlanta, Georgia, that provides direct support to active and retired members of the Special Operations Forces community and their families. It is the sponsor of the Trifecta Research Study — conducted with Johns Hopkins Center for Psychedelic and Consciousness Research — which investigates hormone replacement therapy, magnetic e-resonance therapy (MeRT), ibogaine, and 5-MeO-DMT in combination for the treatment of PTSD and TBI-related cognitive impairment in SOF veterans.

Spital Uster AG is a community hospital in Uster, Switzerland, whose Department of Medicine is affiliated with palliative care physician Sivan Schipper — a member of the Swiss Medical Society for Psycholytic Therapies (SÄPT). Schipper co-authored the landmark Cochrane systematic review of psychedelic-assisted therapy for anxiety, depression, and existential distress in patients with life-threatening diseases, and Spital Uster is associated with Switzerland's LSD-in-palliative-care research program investigating LSD-assisted therapy for anxiety in patients with life-threatening illness.

St Patrick's Mental Health Services (SPMHS) is Ireland's largest independent not-for-profit mental health hospital, located in Dublin, and a leading centre for ketamine research in Ireland. In collaboration with Trinity College Dublin's Professor Declan McLoughlin, it has run the KITE-Dep study (ketamine interleaved with ECT), the KARMA-Dep pilot RCT, and the definitive KARMA-Dep-2 randomised clinical trial — the most rigorous investigation of repeated IV ketamine infusions as adjunctive inpatient therapy for major depression conducted in Ireland.

St. Joseph's Healthcare Hamilton (SJHH) is a multi-site academic health sciences centre in Hamilton, Ontario, Canada, home to the new Centre for Health Innovation and Research in Psychedelics — one of Canada's first dedicated psychedelic research centres. It serves as a test site for the PSYCHED-PAL trial investigating psilocybin microdosing for psychological and existential distress in palliative care patients, and is also conducting trials of psilocybin for cannabis use disorder and chronic pain, with plans to study ketamine, MDMA, and DMT across a broad range of therapeutic indications.

At the Stanford School of Medicine, researchers from the Rodriguez Lab and the Heifets Lab have united under the banner of the Stanford Psychedelic Science Group. Their primary clinical focus is to investigate compounds including ketamine, psilocybin, and MDMA as potential treatments for debilitating disorders such as obsessive-compulsive disorder (OCD), treatment-resistant depression, and post-traumatic stress disorder (PTSD).

Stella (originally Stella Center, now Stella Mental Health) is a US-based psychiatric practice specializing in interventional psychiatry for PTSD, depression, and anxiety, with a particular focus on military veterans and Special Operations Forces personnel. The organization pioneered the Dual Sympathetic Reset (DSR) — an advanced stellate ganglion block (SGB) protocol — alongside ketamine therapy and Spravato, and is involved in the Reversal of Battle-Related Aging (ROBRA) study investigating interventional approaches to combat-related neurological decline in Special Operations Forces cohorts.

Stockholm University is a major public research university in Stockholm, Sweden, known for its strong departments in psychology, neuroscience, and the social sciences. It is one of 19 European partner institutions in PsyPal — the first EU-funded multicenter randomised controlled trial of psilocybin-assisted therapy for psychological distress in palliative care patients with progressive incurable illnesses including COPD, multiple sclerosis, ALS, and atypical Parkinson's disease, awarded over €6.5 million in Horizon Europe funding.

Major academic hospital in Toronto affiliated with the University of Toronto. Contributes to Canadian psychedelic research through its Odette Cancer Centre's involvement in psilocybin trials for cancer-related distress, and its Department of Psychiatry's participation in CANMAT task forces on psychedelic treatments for depression.

Sunstone Medical (operating as Sunstone Therapies) is a US-based clinical-stage organization headquartered in Rockville, Maryland, that focuses on developing and delivering psychedelic-assisted therapy in the medical setting at its purpose-built Bill Richards Center for Healing at Adventist HealthCare Shady Grove Medical Center. It runs trials of psilocybin for major depression in adults with cancer (in collaboration with COMPASS Pathways and Johns Hopkins), MDMA-assisted therapy for adjustment disorder in cancer patient-caregiver dyads, and psilocybin for sexual assault-related PTSD (SUN004).

Directed by Dr. Joji Suzuki, the lab at Brigham and Women's Hospital (Mass General Brigham) is launching clinical trials on psilocybin-assisted therapy for substance use disorders, with a recent focus on Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD).

Swinburne University of Technology is a public university based in Melbourne, Australia, known for its focus on technology, industry partnerships, and applied research. It operates multiple campuses (including Hawthorn and an international campus in Sarawak, Malaysia) and offers on-campus and online study options.

Swiss medical society founded in 1985 whose members received special permission from the Swiss Federal Office of Public Health to conduct psychedelic-assisted therapy with MDMA and LSD in private practices from 1988 to 1993, treating approximately 170 patients. SÄPT continues to advance psycholytic therapy through research, training, and individual treatment licenses, and sponsored the LSD-Assist Study demonstrating persistent anxiety reductions at two-year follow-up.

Swissmedic electronic vigilance infrastructure for adverse drug reaction reporting by healthcare professionals and companies in Switzerland. Included as core safety infrastructure; psychedelic-specific public slices are limited.

The University of Sydney is Australia's oldest university, founded in 1850, with internationally recognized research programs in medicine, pharmacy, and addiction medicine. Its Faculty of Medicine and Health contributes to cutting-edge ketamine research, including as a collaborating institution in the KET-DUAL pilot study — investigating ketamine-enhanced therapy for individuals with co-occurring alcohol use disorder and depression — conducted through the Drug Health Services at Royal Prince Alfred Hospital in Sydney.

Australian adverse-event notification database and safety-monitoring framework. Psychedelic relevance: TGA publishes dedicated policy and access guidance for MDMA and psilocybin use.

Tactogen is a Palo Alto-based public benefit corporation developing novel MDMA-like entactogens and psychedelic-adjacent molecules for psychiatric disorders. Founded in 2020 by neuroscientist Matthew Baggott and Luke Pustejovsky, Tactogen has built the largest known library of entactogenic compounds. Lead candidate TACT908 is a non-hallucinogenic 5-HT1B/2A agonist for cluster headache, while TACT833 targets alcohol use disorder and eating disorders. Following the 2024 FDA rejection of Lykos's MDMA, Tactogen has pivoted toward its novel NCE pipeline.

Taipei Veterans General Hospital (TVGH) is a prestigious tertiary-care academic hospital in Taipei, Taiwan, and home to the Precision Depression Intervention Center (PreDIC) — one of Asia's leading centers for ketamine and esketamine treatment of depression. TVGH has conducted pioneering studies of dose-related adjunctive ketamine for genotyped Taiwanese patients with treatment-resistant depression, low-dose ketamine for TRD with prominent suicidal ideation, and low-dose ketamine infusion for adolescents with treatment-resistant depression.

Tasman Therapeutics is a private US clinical-stage company developing R-107 — a once-daily oral extended-release ketamine tablet targeting treatment-resistant depression. A spinout of Douglas Pharmaceuticals (New Zealand's largest pharma company), Tasman operates as an independently financed US entity led by CEO Dan Browne (co-founder of Revance Therapeutics). Phase 2 BEDROC trial results published in Nature Medicine (March 2024): ~75% remission within one week, 6.1-point MADRS reduction vs. placebo at 12 weeks, median dissociation score of zero (no clinically significant dissociation), 90% continuance into OLE. A 106-patient compassionate supply cohort has taken R-107 at home for an average >2 years without dissociation or monitoring requirements. Phase 3 ROCKET Program (US, EU, international sites) is enrolment-ready; $175M Series A announced April 2025. FDA submission targeted 2027, potential commercialisation 2028. Peak sales projected >$2B.

Tel Aviv University has established the Institute for Integrative Psychedelic Research (IPR-TLV). The IPR-TLV aims to promote interdisciplinary research on psychedelics, focusing on the study of brain-mind-body associations with the goal of revolutionizing mental health.

Terran Biosciences is a New York-based drug discovery platform company developing transformative therapeutics for neurological and psychiatric diseases. Founded by CEO Samuel Clark, the company holds over 200 patent applications covering novel formulations of psychedelic compounds including LSD, DMT, psilocybin, and MDMA, and operates clinical programs in schizophrenia and depression. Its AI-enabled neuromelanin MRI software platform NM-101 has received FDA clearance.

The US subsidiary of Teva Pharmaceutical Industries, one of the world's largest pharmaceutical companies. Teva is known globally as a leader in generic medicines and also markets specialty branded drugs for neurological, respiratory, and oncology conditions, with headquarters in Israel and major operations worldwide.

A public research university located in Lubbock, Texas, with a Health Sciences Center conducting biomedical and clinical research across multiple Texas campuses. Texas Tech offers programs in medicine, pharmacy, nursing, and the health professions, with research spanning psychiatry, addiction medicine, and neuroscience.

A national nonprofit scientific society of healthcare professionals, researchers, and patient advocates dedicated to advancing pain research, education, and treatment in Canada. The Canadian Pain Society promotes the understanding and effective management of acute and chronic pain through scientific exchange, advocacy, and continuing education.

A world-class scientific institution based in Lisbon, Portugal, operating under the Champalimaud Foundation. The Centre conducts cutting-edge research in neuroscience, cancer biology, and systems biology, while also providing clinical oncology services. Its Neuroscience Programme investigates the neural mechanisms of perception, cognition, and behavior.

An independent international research institute focused on preventing and treating the world's leading causes of death and disability. With centers in Australia, China, India, and the UK, the George Institute for Global Health conducts large-scale clinical trials and population health studies addressing cardiovascular disease, stroke, kidney disease, and mental health.

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is an independent, nonprofit biomedical research institute located on the Harbor‑UCLA campus in Torrance, California. It conducts translational and clinical research across areas such as cancer, infectious disease, and genomics and is affiliated with UCLA’s David Geffen School of Medicine.

A nonprofit neuroimaging and neuroinformatics research organization based in Albuquerque, New Mexico, affiliated with the University of New Mexico. The Mind Research Network specializes in psychiatric and neurological brain imaging research using advanced MRI technologies, studying conditions including schizophrenia, addiction, PTSD, and traumatic brain injury.

The Neurobiology Research Unit (NRU) at Copenhagen University Hospital – Rigshospitalet is a leading neuroimaging center led by Prof. Gitte Knudsen. Specializing in PET and MRI studies of the serotonin system, NRU has conducted landmark research on how psilocybin and other psychedelics modulate brain function and serotonin receptor binding, establishing some of the field’s key mechanistic insights.

The New School for Social Research is the graduate division of The New School in New York City, offering advanced degrees and research in the social sciences, philosophy, and history. It is known for progressive, interdisciplinary scholarship and a history rooted in the University in Exile that supported scholars fleeing fascism in the 1930s.

The Second Affiliated Hospital of Anhui Medical University is a general teaching hospital in Hefei, Anhui Province, China. The hospital's psychiatry and anesthesiology departments participate in clinical research, including studies examining ketamine and related compounds for treatment-resistant depression and perioperative psychiatric outcomes.

The University of Melbourne is a leading public research university in Australia, with medical and psychological sciences programmes contributing to psychedelic and mental health research.

The University of New South Wales (UNSW Sydney) is one of Australia’s leading research universities, based in Sydney. UNSW’s School of Psychiatry and affiliated research centers participate in clinical and translational studies into psychedelic-assisted therapies, including psilocybin and MDMA for depression, PTSD, and substance use disorders.

The University of Queensland (UQ) is a public research university headquartered in Brisbane, Australia. Founded in 1909, it is one of Australia’s leading research and teaching institutions with multiple campuses and a strong international reputation.

Academic medical center in Northeast Texas and part of The University of Texas System. Conducts clinical research across pulmonary medicine, trauma, cardiology, and neurology, and has participated in trials exploring psychedelic and ketamine-assisted therapies.

The University of Western Australia (UWA) is a public research university founded in 1911 and based in Perth, Western Australia, offering undergraduate and postgraduate programs and research across a broad range of disciplines. It is a member of Australia’s Group of Eight and is the oldest university in Western Australia.

Large-scale pharma services and CDMO provider engaged by psychedelic developers for U.S.-based clinical supply and potential commercial manufacturing.

The Thompson Institute is a mental health and neuroscience research, education and clinical hub at the University of the Sunshine Coast that translates research into clinical programs and community training.

A leading tertiary academic medical center in the Heping District of Tianjin, China, affiliated with Tianjin Medical University. The hospital integrates clinical care, medical education, and biomedical research across specialties including cardiology, neurology, psychiatry, and oncology, and is one of the most prominent teaching hospitals in northern China.

Tilburg University is a public research university in Tilburg, the Netherlands, known for social sciences, economics, law, and behavioral research.

Toronto Metropolitan University (formerly Ryerson University) is a public research university in downtown Toronto, Canada. Its psychology, health science, and social science researchers participate in clinical studies on psychedelic-assisted therapy, with faculty investigating the effects of psilocybin and other compounds on mental health outcomes in clinical and community populations.

Transcend Therapeutics is a private, New York-based clinical-stage company developing TSND-201 (methylone), a rapid-acting neuroplastogen for PTSD and other neuropsychiatric conditions. Founded in 2021 by Blake Mandell (CEO), Kevin Ryan (AlleyCorp), and Dr. Benjamin Kelmendi (Yale), the company raised $41.5M from investors including the US Department of Defense. TSND-201 is non-hallucinogenic (no 5-HT2A activity) and requires no structured psychotherapy. Its Phase 2 IMPACT-1 trial met the primary endpoint (March 2025, published JAMA Psychiatry Feb 2026) and the FDA granted Breakthrough Therapy Designation in July 2025. Phase 3 programme is planned for 2026.

Transneural Therapeutics is a Washington-based preclinical biotech spun out from CaaMTech in April 2025, developing AI-engineered non-hallucinogenic neuroplastogens for neuropsychiatric disorders. Lead candidate TN-001 is a dual 5-HT2A partial agonist/5-HT2B antagonist designed to deliver rapid antidepressant efficacy without hallucinations, potentially enabling outpatient dosing. TN-001 is in IND-enabling studies for MDD and PTSD, with preclinical data presented at ACNP 2026. CEO Charmaine Lykins brings experience from Karuna, ACADIA, and MapLight.

Clinical trial patient recruitment and enrollment platform providing multilingual digital pre-screening, referral workflows, and real-time recruitment analytics for sponsors, CROs, and sites.

Australian biotech (formerly Tryp Therapeutics, relisted on ASX following Exopharm acquisition in May 2024) developing psilocybin and psilocin formulations for treatment-resistant conditions. TRP-8802 (oral psilocybin) completed Phase 2a trials for fibromyalgia and binge eating disorder. TRP-8803 (IV psilocin) has entered Phase 1 with first-in-human dosing.

Led by Dr. Peter Hendricks, UAB's psychedelic research focuses on utilizing psilocybin-facilitated psychotherapy for substance use disorders, specifically cocaine dependence and smoking cessation, backed by federal NIH research grants.

UC Berkeley School of Public Health (Berkeley Public Health) is the public health school of the University of California, Berkeley, offering graduate and professional degrees and conducting research and public health practice across areas such as epidemiology, biostatistics, environmental health, and health policy.

A leading public research university and health sciences campus in San Francisco, California, part of the University of California system. UCSF is renowned for its medical school, research hospitals, and institutes conducting breakthrough research across neuroscience, psychiatry, oncology, and pharmacology, including emerging work on psychedelic-assisted therapies.

The University of New Mexico has a long history of psychedelic science, dating back to Rick Strassman's DMT studies. Current research at UNM Health Sciences evaluates psilocybin, ketamine, and MDMA for treating depression, opioid use disorder, and Methamphetamine addiction.

UTHealth Houston (UT Health) is the health sciences center of the University of Texas System, located in Houston, Texas. It encompasses schools of medicine, public health, dentistry, nursing, and biomedical sciences, conducting clinical and translational research across psychiatry, neuroscience, and substance use disorders with a focus on improving the health of diverse communities.

A federal health sciences university in Bethesda, Maryland, operated by the US Department of Defense to train military physicians and other health professionals. The Uniformed Services University (USU) conducts research relevant to military medicine, including studies on PTSD, traumatic brain injury, and novel psychiatric treatments for service members and veterans.

Toronto-based health system anchored by St. Michael's Hospital and St. Joseph's Health Centre. The Pinnacle Research Group at St. Michael's is running first-of-its-kind MDMA, ketamine, and psilocybin trials for chronic neuropathic pain, establishing Unity Health Toronto as a leading Canadian centre for psychedelic research.

Canadian biotech developing standardised ibogaine therapy protocols for opioid use disorder. Filed a Clinical Trial Application (CTA) with Health Canada for a Phase 1 clinical study. The company has undergone management restructuring and faces ongoing financing challenges.

A leading public research university in Madrid, Spain, known for its strong programs in sciences, medicine, and the humanities. Founded in 1968, the Universidad Autónoma de Madrid (UAM) conducts internationally recognized research in neuroscience, pharmacology, and psychology, contributing to clinical studies on psychoactive substances and mental health.

Universidad Católica de Cuyo is a private Catholic university based in San Juan, Argentina, with faculties spanning medicine, law, and the social sciences. The university’s health sciences researchers participate in clinical studies including trials investigating psychedelic-assisted therapy in collaboration with regional psychiatric institutions in Argentina.

The Department of Organic Chemistry at Facultad de Qu?mica, Universidad de la Rep?blica (Uruguay), is an academic unit focused on teaching and research in organic chemistry.

Universidade Estadual de Campinas (UNICAMP) is a major Brazilian public research university with active psychedelic and mental-health research collaborations, including ICARO (Interdisciplinary Cooperation for Ayahuasca Research and Outreach), which supports ayahuasca-related scientific and translational work.

Universidade Estadual de Feira de Santana is a public Brazilian university with research activity spanning health and behavioral sciences, including work connected to psychedelic research networks.

Universitat Autonoma de Barcelona is a major public research university in Spain with psychiatry and neuroscience programs that have contributed to psychedelic and psychopharmacology research.

Universitat Politecnica de Catalunya is a public university in Barcelona with interdisciplinary scientific capacity that contributes to collaborative research initiatives, including health data and neuroscience-adjacent projects.

Università degli Studi "G. d'Annunzio" Chieti–Pescara (G. d'Annunzio University) is a public research university with campuses in the cities of Chieti and Pescara, Italy, offering undergraduate and graduate programs across medicine, sciences, engineering, humanities, and social sciences.

The Understanding Neuroplasticity Induced by Tryptamines (UNITY) Project was launched at University College London. UNITY represents the first-in-human study of psychedelics at UCL. The team utilizes techniques such as fMRI, eye-tracking and experience sampling to enhance our understanding of the neurobiological mechanisms predicting cognitive and mental health outcomes following psychedelic use, initially investigating the effects of DMT.

The University of Groningen's medical center (UMCG) is a leading European hub for psychedelic research, coordinating the EU-funded €6.5M PsyPal clinical trial studying psilocybin for psychological distress in palliative care patients. UMCG also hosts an annual interdisciplinary summer school in psychedelic research in collaboration with the OPEN Foundation and partner universities.

Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.

University Hospital Frankfurt (Universitätsmedizin Frankfurt) is the academic medical center affiliated with Goethe University Frankfurt, founded in 1914. It is a major teaching and research hospital providing a wide range of clinical services in Frankfurt am Main, Germany.

The University Hospital of North Norway (Universitetssykehuset Nord-Norge, UNN) is the regional academic hospital for northern Norway and the world's northernmost university hospital. Based in Tromsø, UNN provides specialized healthcare to northern Norway and conducts clinical research in psychiatry, oncology, and other specialties in collaboration with UiT The Arctic University of Norway.

University hospital affiliated with the University of Bonn and one of Europe's leading academic medical centers. Its psychiatry and neuroscience departments have contributed to research on psychedelic-assisted therapies and novel treatments for mood and anxiety disorders.

The Strasbourg University Hospitals (Hôpitaux Universitaires de Strasbourg / CHRU de Strasbourg) is a major academic medical center in Alsace, France, affiliated with the University of Strasbourg. It is one of the largest university hospital groups in France, providing comprehensive tertiary care and conducting clinical research across psychiatry, neurology, and other specialties.

The University Medical Center Groningen (UMCG) is the academic hospital affiliated with the University of Groningen, providing tertiary and specialized patient care while conducting medical research and education. It is one of the largest university hospitals in the Netherlands and serves as the main academic medical center for the northern Netherlands.

The PsyPal project coordinators at UMCG are leading a major EU-funded multi-site clinical study investigating psilocybin therapy for psychological and existential distress in patients with progressive incurable illnesses, including ALS.

The University Psychiatric Clinics Basel (Universitäre Psychiatrische Kliniken Basel, UPK) is a leading psychiatric hospital in Switzerland affiliated with the University of Basel. UPK Basel provides comprehensive inpatient and outpatient psychiatric care and conducts internationally recognized research in psychopharmacology, consciousness studies, and psychedelic-assisted therapy.

A public research university in Tarragona, Catalonia, Spain, with a focus on sciences, health sciences, and technology. The Universitat Rovira i Virgili (URV) conducts research in pharmacology, neuroscience, and behavioral science, with studies exploring the therapeutic potential of psychedelic substances and their neurobiological mechanisms.

The University at Albany, State University of New York (UAlbany) is a public research university located in Albany, New York. It is a University Center of the SUNY system offering undergraduate, graduate, and professional programs across a wide range of disciplines.

The University at Buffalo School of Public Health and Health Professions (SPHHP) is UB’s school for public health and allied health professions, offering undergraduate, graduate, and professional programs and conducting research and community health initiatives from its campus in Buffalo, New York.

Major research university and academic medical center in Birmingham, Alabama. A key site in the first federally funded psilocybin trial in 50 years — a NIH/NIDA-funded multisite study on psilocybin for smoking cessation led by Dr. Peter Hendricks, alongside Johns Hopkins and NYU.

The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.

Although the University of Arizona may not have a dedicated psychedelic research group, one of the first modern clinical trials investigating the use of psychedelics to treat a mental disorder was conducted at the University. In 2006, Dr Francisco Moreno led the first FDA-approved study in 25 years using psychedelics at UA. The study examined the use of psilocybin to treat symptoms of obsessive-compulsive disorder (OCD). Since then, researchers within the Department of Psychiatry at UA have maintained their interest in the field. Dr Moreno, along with Dr Brian Bayze and their research group, is continuing to conduct research into this particular area of psychedelic science at UA ever since the 2006 trial. There is a trial underway at UA exploring the effects of psilocybin on OCD.

The University of Auckland hosts academic psychedelic research activity, including work led by Professor Suresh Muthukumaraswamy on LSD microdosing and related mental health applications.

The University of Barcelona (Universitat de Barcelona, UB) is a public research university in Barcelona, Catalonia, Spain, founded in 1450. It is one of Spain's largest and oldest universities, offering a wide range of undergraduate and postgraduate programs and active in research.

The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.

The University of Bradford is a public research university in Bradford, West Yorkshire, England. It offers undergraduate and postgraduate programs across a range of disciplines and has a strong focus on research and social inclusion.

The University of British Columbia is a Canadian public research university with major campuses in Vancouver and the Okanagan. Its clinical and behavioural research activity includes investigator-led studies relevant to psychedelic-assisted therapy and mental health.

UBA is home to the Consciousness, Culture and Complexity Lab which consists of a multidisciplinary team devoted to the quantitative analysis of high-throughput field and naturalistic studies of human consciousness and cognition. Their sister lab, Phalaris, is specifically dedicated to using psychedelics to study these aspects of neuroscience. Enzo Tagliazucchi oversees the work at both labs. As well as conducting clinical research with psychedelics, Enzo and the team at Phalaris work to make psychedelics visible as native substances of the American continent and advocate for an evidence-based approach toward drug policy.

The Institute for Psychedelics and Neurotherapeutics (IPN) at UC Davis explores the neuroscience of psychedelics. Under the lead of David Olson, the team conducts high-impact interdisciplinary psychedelic science using modern neurobiology and chemistry tools. Contributions by the group include discovering that psychedelics promote neural plasticity, developing a biosensor for measuring hallucinogenic potential, and designing non-hallucinogenic psychedelic analogues with therapeutic potential.

The Psychedelics and Health Research Initiative (PHRI) focuses heavily on conducting pilot studies and clinical trials while collecting diverse biometric data—including fMRI, EEG, and cognitive metrics—from study participants. This data-driven approach aims to unravel the biological and neurological underpinnings of how psychedelics facilitate healing.

The University of California, Los Angeles (UCLA) is a public research university in Los Angeles, California, and a member campus of the University of California system. It offers a wide range of undergraduate, graduate, and professional programs and is known for strong research, healthcare, and arts programs.

University of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.

The Cambridge Psychedelic Research Group (CPRG) brings together scientists, psychiatrists, and clinical psychologists to rigorously advance psychedelic-assisted therapy for mental health. The CPRG initiated its first clinical trials focusing on psychedelic-assisted therapy for post-traumatic stress disorder (PTSD). Currently, the center is initiating additional trials to investigate the therapeutic potential of psilocybin for adults suffering from treatment-resistant depression and generalized anxiety disorder.

The University of Chicago (UChicago) is a private research university located in the Hyde Park neighborhood of Chicago, Illinois. It is known for rigorous scholarship and influential research across the humanities, social sciences, and sciences.

The CU Denver Center for Psychedelic Research is committed to advancing research and education on the therapeutic effects of psychedelic drugs. Led by a multidisciplinary team of experts in psychology, medicine, and public policy, the center focuses on treating emotional, behavioral, psychiatric, and neurologic conditions, as well as providing palliative care for late-stage cancer and chronic diseases. Launched in June 2024, the center aims to inform public policymakers about the potential applications of psychedelics for various medical conditions.

The Neurobiology Research Unit (NRU) at Copenhagen University Hospital has been carrying out clinical and preclinical research with psychedelics since 2017. The team at the NRU utilizes various neuroimaging techniques to better understand how psychedelics exert their effects on the brain. They have published numerous peer-reviewed articles on psychedelics and facilitated numerous medium-dose psilocybin sessions. The NRU is led by Professor Gitte Moos Knudsen.

The Department (Clinic) of Psychiatry and Psychotherapy at the University of Debrecen Clinical Centre provides inpatient and outpatient psychiatric care and functions as a center for education and research in psychiatry and psychotherapy.

The University of Dublin, Trinity College (Trinity College Dublin) is Ireland's oldest university, founded in 1592. A leading research-intensive institution, Trinity conducts internationally recognized research in neuroscience, psychiatry, and pharmacology, including emerging work on psychedelic medicine and consciousness science through its School of Medicine and affiliated research centres.

The University of Exeter is a public research university located in Exeter, England. It operates multiple campuses including Streatham and St Luke’s in Exeter and a campus at Penryn in Cornwall.

The University of Fribourg (Université de Fribourg / Universität Freiburg) is a public bilingual (French and German) university located in Fribourg, Switzerland, offering undergraduate and graduate programs across the humanities, sciences, law, theology and other disciplines.

A major public research university in Geneva, Switzerland, with a strong Faculty of Medicine conducting clinical research in psychiatry, pharmacology, and neuroscience. The University of Geneva has a long tradition in psychopharmacology research and contributes to international clinical trials on psychedelic-assisted therapies in collaboration with Geneva University Hospitals (HUG).

The University of Gothenburg is a public research university located in Gothenburg, Sweden. Founded in 1954 through a merger of local colleges, it offers a broad range of disciplines across multiple faculties.

The Psychedelic and Exceptional Experience Laboratory (PEEL) operates within the Institute for Lifecourse Development at the University of Greenwich. Led by Prof David Luke, Professor of Exceptional Experience, the lab brings together a team of faculty, alumni, and affiliates who have collectively been researching and publishing peer-reviewed papers on psychedelic and exceptional experiences. PEEL is one of the few research groups specifically looking at exceptional experiences alongside psychedelics, and welcomes postgraduate research opportunities.

A prestigious public research university in Groningen, the Netherlands, founded in 1614. The University of Groningen has a strong Faculty of Science and Engineering and Faculty of Medical Sciences, with research covering pharmacology, neuroscience, and psychiatry, including studies on the mechanisms and therapeutic applications of psychoactive substances.

The University of Iowa is a public research university located in Iowa City, Iowa, United States, founded in 1847. It offers undergraduate, graduate, and professional programs and is known for strong programs in writing, health sciences, and the arts.

The University of Kentucky is a public land-grant research university in Lexington, Kentucky, United States, founded in 1865. It is the state's flagship public university, offering undergraduate, graduate and professional programs and engaging in significant research activity.

Clerkenwell Health is collaborating with researchers at the University of Manchester to run Phase II studies. Trials here aim to assess the impact of talking therapy informed by Perceptual Control Theory alongside different doses of psilocybin, led by Dr Sara Tai who has previously been involved with Compass Pathways.

The University of Maryland School of Medicine (UMSOM), founded in 1807 and located in Baltimore, Maryland, is the medical school of the University of Maryland, Baltimore. It provides medical education, biomedical research, and clinical patient care and is affiliated with the University of Maryland Medical Center.

The University of Maryland, Baltimore (UMB) is Maryland’s public health and professional sciences university, housing schools of medicine, pharmacy, dentistry, nursing, law, and social work. UMB’s School of Medicine participates in clinical trials investigating psychedelic-assisted therapies including psilocybin for depression and ketamine-based treatments for psychiatric conditions.

The Melbourne School of Population and Global Health is an academic unit within the University of Melbourne's Faculty of Medicine, Dentistry and Health Sciences. It conducts research and trains public health leaders to improve health equity, with emphasis on Indigenous health and global public health.

The University of Miami Leonard M. Miller School of Medicine is the medical school of the University of Miami in Miami, Florida. It is a research-intensive institution that provides medical education, conducts biomedical research, and delivers clinical care as part of the University of Miami Health system.

The Michigan Psychedelic Center (M-PsyC) at the University of Michigan Medical Center was launched in 2022 to span the psychedelic research landscape, from foundational discovery to clinical implementation.

The Nielson Lab at the University of Minnesota is dedicated to understanding and treating trauma. More recently, the team here has been diving into psychedelic neuroscience research and drug policy reform thanks to funding from the newly created Psychedelic-Assisted THerapy (PATH) Fund at the UMN Foundation. The lab has been collecting survey data to assess the benefits and risks of ayahuasca use in naturalistic settings to treat symptoms of trauma. Additionally, Dr Jessica Nielson and her team are researching the neurological mechanisms of altered states of consciousness and their role in promoting neuroplasticity and wellness in healthy research participants.

The University of Mississippi Medical Center (UMMC) is the health sciences campus of the University of Mississippi, located in Jackson, Mississippi. It is the state’s only academic medical center, providing medical education, research, and advanced clinical care.

At the University of Nebraska Medical Centre research with psychedelics is underway. At the UN Medical Centre, Associate Professor of Palliative Medicine, Lou Lukas is using psychedelics to improve the quality of life of people in palliative care. Dr Lukas is part of a wider research team consisting of various medical professionals affiliated with the University of Nebraska that explores the use of psychedelics in palliative care. The Heartland Palliadelic Research Centre was created to complement existing disease-based research by exploring the potential of psychedelics to help people with serious illness increase resilience and reduce suffering for themselves and their families.

Pioneer in modern American psychedelic research through Rick Strassman's DMT and psilocybin studies in the 1990s — among the first human psychedelic research since the 1970s. Today, UNM Health Sciences conducts active trials of psilocybin, MDMA, and ketamine for depression, PTSD, alcohol use disorder, and methamphetamine addiction.

UNSW and the Black Dog Institute are Australian academic and clinical research partners with programs in mental health and emerging psychedelic therapeutics research.

The University of North Carolina at Chapel Hill School of Medicine (UNC School of Medicine) is the medical school of the University of North Carolina at Chapel Hill. It provides MD and graduate medical education, conducts biomedical research, and delivers clinical care through UNC Health and UNC Medical Center.

The University of North Carolina at Chapel Hill (UNC-CH) is North Carolina’s flagship public research university. UNC’s Psychiatry and behavioral science researchers participate in clinical trials investigating psychedelic-assisted therapies for conditions including depression, anxiety, PTSD, and substance use disorders, supported by NIH and other research funding.

The Psykedelika-gruppen at the University of Oslo brings together researchers studying the recreational and therapeutic uses of psychedelics. Their projects include surveys on psychedelic use and clinical studies on MDMA for treating depression.

The University of Otago, founded in 1869, is New Zealand's oldest university with its main campus in Dunedin and additional campuses and centres across the country; it is known for strong health sciences and research.

The University of Ottawa (uOttawa) is a bilingual public research university in Ottawa, Ontario, Canada. It offers undergraduate and graduate programs in both English and French and is one of Canada’s major research-intensive universities.

The University of Ottawa launched a groundbreaking one-year MA in Psychedelics and Consciousness Studies in 2024, jointly offered by the Faculty of Social Sciences and Faculty of Arts under co-directors Dr. Monnica Williams and Dr. Anne Vallely. The program builds on earlier microprograms in Psychedelic Science and Psychedelics & Spirituality Studies established since 2020, training licensed professionals, clergy, and researchers in therapeutic, spiritual, and academic dimensions of psychedelics.

The Department of Psychiatry at the University of Oxford is a clinical department within the Medical Sciences Division that conducts research, teaching, and clinical trials across psychiatry, neuroscience, and mental health. It is based at the Warneford Hospital site in Oxford, England.

The Penn Psychedelics Collaborative at the University of Pennsylvania is a multi-school consortium of researchers, clinicians, and faculty advancing transdisciplinary psychedelic science across Penn Medicine and Penn Nursing, including clinical trials of MDMA-assisted therapy and psilocybin research. Penn researchers are also leading the development of bioethical guidelines for psychedelic-assisted therapy and community implementation frameworks.

The University of Puerto Rico is the principal public university system of Puerto Rico, encompassing eleven campuses including the flagship Río Piedras campus and the Medical Sciences Campus in San Juan. The university conducts biomedical and social science research relevant to mental health, substance use, and the health needs of Caribbean and Latino populations.

The University of Saskatchewan is a public research university located in Saskatoon, Saskatchewan, Canada. Founded in 1907, it is a member of the U15 group of Canadian research universities and offers a wide range of undergraduate and graduate programs.

The University of Siena (Università degli Studi di Siena) is a public research university in Siena, Tuscany, Italy, founded in 1240 and one of Italy's oldest universities. It offers a wide range of undergraduate and postgraduate programs and is known for strengths in law, medicine, humanities, and social sciences.

The University of Southern California (USC) is a private research university in Los Angeles, California, United States. Founded in 1880, it offers undergraduate and graduate programs across a wide range of fields and is known for its professional schools and research activities.

The Brain and Mind Centre is advancing psychedelic science with a multidisciplinary focus on developing innovative treatments using AI and preparing for human clinical trials to treat severe mental illness.

UT Southwestern Medical Center is a leading academic medical center in Dallas, Texas, combining research, education, and patient care. It houses the Peter O'Donnell Jr. Brain Institute and participates in clinical trials investigating ketamine and psychedelic-adjacent compounds for treatment-resistant depression and other neuropsychiatric conditions.

The Center for Psychedelic Research and Therapy within the Dell Medical School conducts clinical research with various psychedelics, including psilocybin, MDMA, ibogaine, and ayahuasca. A major and unique focus of the center at UTA is its dedication to using psychedelics to treat military veterans suffering from PTSD, as well as adults experiencing prolonged grief disorder and those who have survived childhood trauma.

University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.

The Psychedelic Studies Research Program (PSRP) distinguishes itself by adhering strictly to the principles of Open Science, pre-registering their analysis plans, and making their data and protocols freely accessible. A primary focus for the team at the PSRP is the clinical study of microdosing. Led by Dr. Norman Farb, the program conducts double-blind, randomized controlled trials investigating the benefits and drawbacks of microdosing very low doses of psilocybin.

The University of Turku is a multidisciplinary public research university in Turku, Finland, with active biomedical and health research programs.

The University of Utah College of Social Work (based in Salt Lake City) offers accredited BSW, MSW, and PhD programs and was established to train social work professionals. It also conducts research and community-engaged work addressing social welfare, policy, and practice in the Intermountain West.

At UW, researchers are working on clinical trials with psilocybin (provided by Usona). Dr Anthony Back, co-director of the University's Center for Excellence in Palliative Care, led a trial exploring the effects of psilocybin to alleviate the mental health burden inflicted on frontline healthcare workers throughout the COVID-19 pandemic. As Seattle became the largest city in the US to decriminalise psilocybin mushrooms in October 2021, and with ongoing legislative efforts at the state level, more research with psychedelics is anticipated and occurring at UW.

The University of Wisconsin Department of Family Medicine and Community Health is an academic clinical department supporting research and translational work in mental health, primary care, and related psychedelic medicine studies.

The University of Wisconsin-Madison Transdisciplinary Center for Research in Psychoactive Substances is dedicated to exploring the scientific, historical, and cultural aspects of psychoactive substances, focusing on psychedelics.

The University of Wisconsin–Madison School of Medicine and Public Health (SMPH) is the medical and public health school of the University of Wisconsin–Madison, providing education, research, and clinical partnerships to improve health in Wisconsin and beyond.

The University of Wisconsin–Madison School of Pharmacy is the pharmacy school of the public research university UW–Madison, located in Madison, Wisconsin. It offers professional (PharmD), graduate and research programs in pharmaceutical sciences, clinical pharmacy, and related fields.

The University of Wollongong School of Psychology is an academic unit of the University of Wollongong (Wollongong, New South Wales) that delivers undergraduate and postgraduate psychology programs and conducts research across clinical, health, developmental and cognitive psychology areas.

Within the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.

WHO collaborating centre for international drug safety monitoring, stewarding VigiBase and global pharmacovigilance methods.

One of Scandinavia's oldest and most prestigious research universities, founded in Uppsala, Sweden in 1477. Uppsala University has a strong Faculty of Medicine and Pharmacy with research groups studying pharmacology, neuroscience, and psychiatry, including the mechanisms of action and clinical applications of psychoactive compounds.

Usona Institute is a US-based 501(c)(3) non-profit medical research organisation (MRO) headquartered in Madison, Wisconsin. Co-founded in 2014 by Bill Linton (CEO of Promega Corporation) and Malynn Utzinger, M.D., Usona was established after Linton witnessed the profound impact of a Johns Hopkins psilocybin study on a terminally ill friend. Unlike commercial drug developers, Usona operates as a mission-driven MRO — conducting and supporting pre-clinical and clinical research on psilocybin and other consciousness-expanding medicines, with the goal of developing accessible, affordable treatments. Its research leadership includes Dr. Charles Raison (Director of Clinical and Translational Research, UW-Madison psychiatrist) and Dr. Alexander Sherwood (medicinal chemist). Usona's psilocybin programme received FDA Breakthrough Therapy Designation for major depressive disorder in 2019. After completing the Phase 2 PSIL201 study (the largest Phase 2 randomised controlled trial of psilocybin for MDD at the time), the Institute launched the Phase 3 uAspire trial in 2024 — a 240-participant, randomised, double-blind, multicentre study comparing 25 mg psilocybin vs placebo in adults with MDD. Usona is also exploring 5-MeO-DMT in early-stage research.

A research institute within Utrecht University's Faculty of Science in the Netherlands, conducting research on drug discovery, pharmacology, and pharmaceutical sciences. UIPS studies include the pharmacokinetics, toxicology, and neurobiological effects of psychoactive compounds, and contributes to translational research bridging laboratory pharmacology and clinical application.

Some researchers at Utrecht University are working on a large psychedelics study with colleagues from Leiden University, exploring varying intersections of mental health and psychoactive substances.

Led by Dr. Steve Marder and Dr. Walter Dunn, the VA Greater Los Angeles Healthcare System is at the forefront of the VA's expanding psychedelic research program. This initiative, supported by Healing Breakthrough, includes studies on MDMA and psilocybin for PTSD and depression. Note: This is part of a broader network of 13+ VA medical centers (including Bronx, Omaha, and Palo Alto) now pioneering psychedelic-assisted therapies for veterans.

In response to the fallout from the COVID-19 pandemic, a research group at Vancouver Island University (VIU) has been awarded funding from the Canadian Institutes of Health Research for the exploration of psychedelic therapies for front-line workers. Led by Dr Shannon Dames, the team are currently focusing on ketamine-assisted therapy for front-line workers experiencing symptoms of PTSD and emotional distress as a result of their experiences working through the pandemic.

Vanderbilt University Medical Center (VUMC) is a leading academic medical center in Nashville, Tennessee, known for its research strengths in neuroscience and psychiatry. It participates in clinical research on psychedelic-assisted therapies including psilocybin and MDMA for treatment-resistant depression, PTSD, and other psychiatric conditions.

A physician-founded, science-focused medical cannabis company operating cultivations, manufacturing facilities, and dispensaries across multiple US states. Vireo Health integrates medical expertise and pharmaceutical-grade production to provide cannabis-based treatments to patients, with operations in Maryland, Minnesota, and New York and a focus on evidence-based medicine and patient care.

WHO global trial-search aggregator across multiple primary registries. Psychedelic records are present via source registries, but ICTRP does not provide a dedicated psychedelic evidence vertical.

Wake Forest University School of Medicine and its clinical affiliate Atrium Health Wake Forest Baptist form a comprehensive academic health sciences enterprise in Winston-Salem, North Carolina. The institution conducts extensive clinical and translational research in psychiatry, neuroscience, addiction medicine, and novel therapeutic approaches, including studies on psychedelic-assisted treatment.

The Program in Psychedelic Research (PiPer) is a partnership between The Healthy Mind Lab, the Washington University Neuroimaging Lab, and Usona Institute. PiPer leverages 30 years of neuroimaging research and four decades of psychiatry research. The group has started with four research projects around neuroimaging data in humans and animals. The university also serves as a site for Usona's Phase II/III trial with 25mg of psilocybin.

A public research university in Morgantown, West Virginia, with a comprehensive health sciences center including the WVU School of Medicine. The university conducts biomedical and clinical research addressing Appalachian health disparities, including studies on substance use disorders, addiction medicine, and novel psychiatric treatments relevant to the region's ongoing opioid crisis.

NICM Health Research Institute is a research institute of Western Sydney University focused on integrative and complementary medicine, conducting preclinical, clinical and translational research to evaluate the quality, safety, and effectiveness of traditional and complementary therapies.

Western University (University of Western Ontario) is a leading public research university in London, Ontario, Canada. Its Schulich School of Medicine & Dentistry conducts clinical and neuroscientific research in psychiatry, pharmacology, and behavioral science, with research interests including the therapeutic mechanisms of psychedelic and psychoactive compounds in mental health treatment.

An Australian biotech company developing proprietary synthetic psilocybin formulations and novel psychedelic therapies for mental health disorders. Woke Pharmaceuticals sponsors clinical trials for treatment-resistant depression partnering with leading universities including Swinburne University and the University of Western Australia, and is developing novel LSD analogues through research collaboration aimed at improving therapeutic profiles.

Women’s Hospital, School of Medicine, Zhejiang University is a specialized women’s hospital in Hangzhou, China, affiliated with Zhejiang University. Founded in 1951, it is a major center for reproductive medicine and gynecologic research with over 1,120 beds, participating in clinical studies including ketamine-based therapies for perioperative depression and psychiatric conditions.

Global full-service CRO with a dedicated psychedelic center of excellence supporting psychiatry-focused psychedelic clinical development programs, including large multicountry studies.

A comprehensive teaching hospital of Central South University in Changsha, Hunan Province, China, with a history dating to 1906. One of China's leading academic medical centers, Xiangya Hospital integrates clinical care, medical education, and research across psychiatry, neurology, pharmacology, and other specialties, conducting international-standard clinical trials.

Xpira Pharmaceuticals is a Toronto-based private biotech developing psilocybin-assisted therapy for anorexia nervosa (AN), a condition with no currently approved pharmacological or psychotherapeutic treatments. Founded in 2020 by leaders from the Canadian and Dutch pharmaceutical industries, the company received FDA IND approval in September 2022 for a Phase 2a clinical trial. Xpira is a portfolio company of Origin Therapeutics Holdings. Dr. Allan Kaplan of CAMH and the University of Toronto serves as VP of Clinical Development.

Xylo Bio (formerly Psylo) is an Australian-US biotech developing next-generation neuroplasticity-promoting therapeutics for mental health. Founded in 2021 by Josh Ismin and Sam Banister in Sydney, the company has labs at the University of Colorado Boulder and the University of New South Wales. Its lead candidate PSYLO-100X is a non-hallucinogenic compound designed for home administration without clinical supervision, advancing through IND-enabling studies toward first-in-human trials. Xylo has raised $14.2M including an $8M seed round in June 2024 from Tenmile, Focalpoint Partners, and Palo Santo.

A research center within Yale School of Medicine focused on understanding the neuroscience of consciousness, mental health disorders, and the mechanisms of psychoactive substances. The Center for Brain and Mind Health bridges psychiatry and neuroscience to advance knowledge of brain-mind relationships and explore novel therapeutic approaches including psychedelic-assisted treatment at Yale.

In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.

A public comprehensive university in Yangzhou, Jiangsu Province, China, with programs spanning medicine, science, engineering, and the humanities. Yangzhou University's medical college conducts clinical research in collaboration with regional hospitals, contributing to studies on psychiatric conditions and novel pharmacological interventions.

Yonsei University is a leading private research university in Seoul, South Korea, with major medical and life-science research institutions.

Zylorion Health (formerly PsiloTec Health Solutions) is a Calgary-based biotech company developing integrated precision mental health therapies. Its proprietary Almond Therapy™ program combines psychedelic compounds with structured psychotherapy, and the company is advancing psilocybin-based clinical trials for treatment-resistant depression and PTSD alongside a novel second-generation psilocybin compound (ZYL-314) in its pipeline.

atai Life Sciences (operating as atai Therapeutics, Inc. in the US) is a publicly traded clinical-stage biopharmaceutical company founded in 2018 with the largest and most diverse portfolio of psychedelic-derived drug candidates, including DMT, R-MDMA, psilocin, 5-MeO-DMT (BPL-003), and ibogaine for depression, anxiety, and addiction. Following its 2024 merger with Beckley Psytech to form AtaiBeckley, BPL-003 received FDA Breakthrough Therapy designation for treatment-resistant depression with Phase 3 trials anticipated in 2026.

PsykForsk is an official clinical research group at Østfold Hospital in Norway, actively engaged in psychedelic research and rapid-acting antidepressant treatments. The group served as a site for the European MAPS/Lykos MDMA-assisted therapy trial for PTSD, and recently published an investigator-initiated trial on MDMA-assisted therapy for Major Depressive Disorder in the British Journal of Psychiatry. Their expanding research portfolio includes establishing outcomes for ketamine outpatient clinics and conducting large national multicenter RCTs investigating ketamine maintenance treatment.